


# NEXTGEN BIOMED 2025

12 - 14 March 2025 | London, UK

Conference Brochure



Proudly supported by The Antibody Society, our Scientific Programme Partner

Don't miss the society's presentation by Silvia Crescioli, Business Intelligence Creator.

Stay tuned for her presentation details!



## 250+ Industry-Leading Speakers Including...

From groundbreaking discoveries to real-life applications: bringing the next generation of biomedicines from concept to market



12 Content Tracks



12+ Hours of 1:1 Meetings



50+ Partners




1000+ Attendees

Composed of 6 Groundbreaking Programmes!



Proteins, Antibodies & ADCs



Peptides



Oligonucleotides



Sustainability in Biologics & Tides



Immunotherapy & Immuno-oncology



Vaccines



FERNANDO ALBERICIO  
Research Professor,  
University of Barcelona



FRANCISCA WOLLERTON  
Senior Director Protein Engineering &  
Novel Modalities, AstraZeneca



MARIA KOUFALI  
Director, Research & Innovation,  
UK Vaccine Innovation Pathway



DAVID EVANS  
Chief Scientific Officer,  
Sirnaomics



MARTA AMARAL  
Group Head High Throughput Protein  
Engineering in Large Molecules Research, Sanofi



LIVJIA DEBAN  
Chief Scientific Officer,  
Prokarium



TRISTAN VAUGHAN  
Vice President of Protein  
Engineering, Immunocore



DANIEL LAROCQUE  
Innovation Lead, Innovation and  
Emerging Science, Sanofi



NAZNEEN DEWJI  
Founder & Chief Executive Officer,  
Cenna Biosciences



# WELCOME TO NextGen Biomed 2025

Welcome to NextGen Biomed 2025, Oxford Global's premier event that unites the brightest minds and the latest innovations in biomedicine under one roof.

Join us for three immersive days of expertly curated content tackling the most critical challenges and exciting opportunities across 6 cutting-edge programmes: Proteins, Antibodies & ADCs, Peptides, Oligonucleotides, Sustainability in Biologics & Tides, Immunotherapy & Immuno-Oncology and Vaccines.

Our dynamic agenda showcases the latest innovations and technological advancements in biologics R&D, peptide & oligonucleotide therapeutics optimisation, immunotherapy strategies, vaccine discovery & development, and the shift towards sustainable manufacturing practices. These are further enriched by thought-provoking sessions that unite diverse stakeholders to tackle shared challenges, including the evolving regulatory landscape for biomedicines, collaborative efforts, and strategic partnerships driving market growth.

In addition to groundbreaking presentations and interactive discussions, this event offers invaluable networking opportunities with industry leaders and innovators. Explore our Start-Up Zone

and Innovation & Collaboration track, where emerging technology and therapeutic biotechs showcase breakthrough ideas, and connect with potential collaborators to stay ahead of the next wave of pioneering advancements in biomedicine.

## Eszter Sutowski Nagy

Director of Editorial & Event Content,  
Oxford Global



## Unlock The Latest News & Insights

Sign up for our monthly newsletter to keep up with all things NextGen Biomed

[Click Here](#) 



### BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

[Book Now](#)

LinkedIn

@OGConferences




WHAT'S NEW

## Benefits Of Attending



### Take a deep dive into the latest technological innovations in biologics discovery & development.

Presentations will be covering the display of proteins & antibodies, AI-guided antibody engineering, analytical development with focus on ensuring stability and characterisation updates, multi-specifics development, novel therapeutic formats and insights from upstream & downstream processing.



### Discuss what's novel in peptide discovery & development.

From developments in peptide chemistry through to therapeutics development: key topics to be covered include AI/ML for therapeutics analysis, peptide display & de novo sequencing, peptide design and case studies from oncology, regenerative medicine and many more.



### Stay at the forefront of oligonucleotides discovery & therapeutics optimisation.

Join experts from companies & pioneering biotechs such as Sirnaomics, GSK, Dyne Therapeutics & Novartis to disseminate the latest computational approaches, novel mechanisms of action, overcoming delivery hurdles and progress to clinical trials.



### Immerse yourself in innovations pertaining to peptide & oligo green chemistry, manufacturing, and sustainable supply chain development for biologics.

Presentations will delve into sustainable engineering practices, advanced solvent recovery systems and ensuring supply chain continuity.



### Gain invaluable insights into the latest advancements in immunotherapy, immuno-oncology, and personalised cancer therapies.

Explore cutting-edge strategies in cancer and autoimmune treatments, discover novel therapeutic targets, and delve into the evolving role of the microbiome in immune response coupled with a focus on advanced cell and gene therapies, predictive models, biomarkers, and precision medicine.



### Unlock exclusive insights into next-generation vaccine development, from cutting-edge mRNA and DNA platforms to innovative antigen design and advanced analytical testing.

Discover the latest strategies in vaccine stability, AI-driven optimisations, and preclinical innovations for infectious diseases.

## DON'T MISS THESE Special Features

Regulatory Roundtable Discussions

Thought Leadership Panel Discussions

Fireside Chats

Start-Up Zone

Innovation & Collaboration Programme

Young Scientist Awards

## BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

Book Now

LinkedIn

@OGConferences



# WHY PARTNER WITH OXFORD GLOBAL?

At Oxford Global, our mission is to curate personalised experiences that foster community and inspire innovation.

We believe in the power of networking, connection, and knowledge to deliver quality products and services that exceed expectations. Partnering with Oxford Global means having a dedicated team committed to helping you achieve your goals and navigating the industry's ever-changing landscape.

## ✓ Arrange 1-1 Meetings

Benefit from guaranteed one-to-one face time with your key prospects, with detailed pre-meeting information provided to enable effective and productive conversations.

## ✓ Speaking Opportunities

Showcase your company's recent work to a relevant and highly engaged audience.

## ✓ Host Panel & Roundtable Discussions

Feature alongside key opinion leaders to discuss current hot topics and highlight your company's expertise.

## ✓ Organise Workshops

Demonstrate best practice within the industry in front of your peers with case studies from your clients.

## ✓ Exhibit your Products & Solutions

Promote your offerings and ensure delegates know where to find you with a prominent brand presence in the exhibition hall.

## ✓ Digital Marketing & Lead Generation

Accessing the Oxford Global database, amplify your thought leadership and branding messaging through our digital content initiatives.

[LEARN MORE](#)



DRIVE INNOVATION & ACCELERATE RESEARCH

# Who Is Partnering?

## Gold Sponsors



## Silver Sponsors



## Bronze Sponsors



## Network & Programme Sponsors



## BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

[Book Now](#)

[LinkedIn](#)

[@OGConferences](#)



## EVENT OVERVIEW

# Programme Agenda at a Glance

NextGen Biomed 2025 explores the entire value chain involved in bringing next-generation biomedicines to market. Deep dive into specific tracks, and enjoy cross-programme features bringing our audience together.

	Day One	Day Two	Day Three
Cross-Programme Features	Opening Keynote Address & Fireside Chat with Keynote Speaker Roundtable Discussions Interactive Networking Breaks: Poster Presentations, 1-2-1 Meetings, Fireside Chats and Technology Showcase Presentations End of Day Summaries Networking Drinks at Themed Bars & Canapés Reception	Keynote Addresses Roundtable Discussions Interactive Networking Breaks: Poster Presentations, 1-2-1 Meetings, Fireside Chats, and Technology Showcase Presentations Poster Presentation Awards Ceremony End of Day Summaries Networking Drinks at Themed Bars	Interactive Networking Breaks: Poster Presentations, 1-2-1 Meetings, and Technology Showcase Presentations Panel Discussion: Women in NextGen Biomed
Proteins, Antibodies & ADCs	Antibody Discovery & Selection: Novel Tools & Technologies	Antibody Discovery & Engineering	AI/ML-Guided Protein & Antibody Engineering
	ADC Design, Validation & Optimisation	New Formats: Cytokines, Immunocytokines & Novel Therapeutic Formats	NextGen Multi-Specifics, Cell Engagers & Other New Modalities
	Analytical Development: Stability & Characterisation	Analytical Development: Developability & Quality Control Systems	Novel Strategies for Clinical Development
	Upstream Development of Proteins & Antibodies	Downstream Development for Antibodies and Fc Containing Molecules	Protein Purification & Recombinant Protein Production
Peptides	Peptide Discovery	Peptide Chemistry	Peptide Therapeutics & Development
Oligonucleotides	Oligonucleotide Discovery	Oligonucleotide Chemistry & CMC	Oligonucleotide Therapeutic Development & Optimisation
Sustainability in Biologics & Tides	Peptides & Oligo Green Chemistry	Green Innovations in Peptide & Oligo Manufacturing	Sustainable Supply Chain Development & Commercialisation for Biologics
Immunotherapy & Immunology	Immunotherapy Strategies	New Clinical Developments for Immunotherapies	Microbiome & the Gut-Immune Axis
	Discovery & Development: Cell & Gene and Combination Therapies	Predictive Models & Tools: Preclinical Evaluation & Translational Development	Discovery & Development: Antibody Therapies
	Biomarkers, ctDNA, Precision Medicine & Multi-Omics in Immuno-Oncology	Personalised Cancer Therapies	Novel Targets in Immuno-oncology
Vaccines	Nucleotides, Biologics & Other Vaccine Platforms for Infectious Diseases	Vaccine Analytical Testing & Stability	Preclinical Innovation & Clinical Development for mRNA Vaccines
Innovation & Collaboration	Innovation & Collaboration Presentations, Q&As & Panel Discussions	Innovation & Collaboration Presentations, Q&As & Panel Discussions	Innovation & Collaboration Presentations, Q&As & Panel Discussions

## BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immunology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

Book Now

LinkedIn

@OGConferences



# Proteins, Antibodies & ADCs Programme Overviews

Join leading scientific experts through our annual Proteins, Antibodies & ADCs programme, addressing critical strategies, scientific breakthroughs and the latest technological advancements in protein & antibody engineering, bioanalytical techniques, the latest case studies in the development of next-generation biotherapeutics, and the advancements in upstream & downstream processing.

**VPs, Directors & Senior Managers** from leading pharma & biotech companies and research institutions in the following fields and more:

- Antibody Engineering
- Protein Engineering
- Biotherapeutics
- Analytical Development
- Antibody Technologies
- Antibody Discovery
- Protein Purification
- Clinical Development
- Protein Expression

**Formal and informal meeting opportunities** offer delegates the chance to discuss key solutions with leading service providers:

- Engineering Platforms
- Bioconjugation
- Antibody Generation
- Antibody Humanisation
- Developability Assessment
- Computational Biology
- Bioanalytical Development
- Bispecific Antibody Design
- Expression Systems



“Biologics 2024 was very well attended. The 1-to-1 meetings were very helpful and sets this show apart from the rest.”

- DIRECTOR OF BUSINESS DEVELOPMENT (EUROPE), CPC SCIENTIFIC



Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

Book Now



# Confirmed Speakers

KEY SPEAKERS



Day One | 09:25

Targeting Ion Channels With Antibodies & Antibody Fusion Molecules

**ANEESH KARATT VELLATT**, Chief Scientific Officer, Maxion Therapeutics



Day One | 09:25

Generation Of Bispecific Antibody Conjugates

**JOHN DE KRUIFF**, Executive Vice President, Chief Technology Officer, Merus



Day One | 09:25

Characterisation Of Biotherapeutics

**SARAH STUART**, High Throughput Characterisation Team Leader, GSK



Day One | 09:25

High-Throughput Screening For Biologics

**JENNY FITTING**, Head of AAV and Protein Science, Bayer AG



Day Two | 09:25

Multispecifics High-Throughput Engineering Platforms

**MARTA AMARAL**, Head of High-Throughput Protein Engineering, Sanofi

## PROTEINS & ANTIBODIES SPEAKERS

### JOHN DE KRUIFF

Executive Vice President, Chief Technology Officer, Merus

### ANEESH KARATT VELLATT

Chief Scientific Officer, Maxion Therapeutics

### RAJIKA PERERA

Chief Executive Officer, Poseidon LLC

### SONIA MACIA

Chief Medical Officer, Aromics Therapeutics

### KEVIN FITZGERALD

Chief Scientific Officer, Epsilogen

### TRISTAN VAUGHAN

Vice President of Protein Engineering, Immunocore

### MICHAEL DYSON

Vice President, Antibody Discovery and Engineering, Ichnos Glenmark Innovation

### RICK HIBBERT

Vice President & Head of CMC Science & Technologies, Genmab

### VLADIMIR GLIGORIJEVIC

Senior Director of AI/ML, Genentech

### FRANCISCA WOLLERTON

Senior Director of Protein Engineering and Novel Modalities, AstraZeneca

### ERIK VERNET

Senior Director, External Partnerships & Emerging Technologies, Novo Nordisk Inc.

### TALIP UCAR

Senior Director – AI Research, AstraZeneca

*(RESERVED)*

### BISHNU NAYAK

Senior Director, Neologics Bioscience

### RITA MARTELLO

Scientific Director, NBE DMPK Lead & Head of External NBE DMPK Leads Clinical Activities, Merck KGaA

### STEFAN ZIELONKA

Director and Head of Antibody Discovery and Protein Engineering, Merck Healthcare KGaA

### AMY LI

Director, Drug Discovery, T-Therapeutics

### LAURA STARKIE

Director, UCB

### SIMON HUFTON

Section Head Molecular Immunology, Division of Biotherapeutics, National Institute for Biological Standards and Control

### MATHIEU CINIER

Scientific Director, Affilicog

*(RESERVED)*

### NIKOLAJ DIETRICH

Associate Scientific Director, Therapeutic Innovation Biologic Drug Design, Symphogen

### MATTHEW BURRELL

Associate Director, AstraZeneca

### HENRY MAUN

Associate Director, Genentech

### SIMON KRAH

Associate Director, Protein Engineering & Antibody Technologies, Merck KGaA

### VINCENT DEWAR

Associate Director, GSK

### DARKO SKEGRO

Associate Director- Group Head Biotherapeutic Engineering and Conjugation, Novartis

### BRYCE NELSON

Head of Protein and Antibody Engineering, Orion Corporation

### ALEXEY RAK

Head of Bio Structure and Biophysics, Sanofi

### MARTA AMARAL

Head of High-Throughput Protein Engineering, Sanofi

### DENISE STECKEL

Head of Clinical Collaborations Development, Genentech

### JENNY FITTING

Head of AAV and Protein Science, Bayer AG

### NORBERT FURTMANN

Head of AI Innovation, Sanofi

### KAREN SILENCE

Head Preclinical Product Development, ArgenX

*(RESERVED)*

### MARCO BECHERELLI

CMC Technical Leader Biologics, Chiesi Pharmaceuticals

### TIMOTHY HICKLING

Investigative Safety and Immunosafety Chapter Lead, Hoffmann-La Roche

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

Book Now



# Confirmed Speakers

KEY SPEAKERS



Day Two | 09:25

Antibody-Based Cytokine Mimetics

**STEFAN ZIELONKA**, Director and Head of Antibody Discovery and Protein Engineering, Merck Healthcare KGaA



Day Two | 09:25

Characterisation Of Biologics Through Functional Assays

**KELLY LOYET**, Distinguished Scientist, Genentech



Day Two | 09:00

The Journey From TCR Discovery Through To Approval Green Chemistry in Peptide Synthesis

**TRISTAN VAUGHAN**, Vice President of Protein Engineering, Immunocore



Day Two | 11:40

Novel Target Identification And Validation Approaches

**LAURA STARKIE**, Director, UCB



Day Two | 11:40

Format Explorations For Sweeping Of Highly Abundant Targets

**KAREN SILENCE**, Head Preclinical Product Development, ArgenX

## SARAH STUART

High Throughput Characterisation Team Leader, GSK

## MAJA FIRCIK

HT Expression Team Leader, GSK

## KELLY LOYET

Distinguished Scientist, Genentech

## OBINNA UBAH

Principal Scientist and Future Leaders Fellow, Elasmogen

## PAUL WASSMANN

Senior Principal Scientist, Novartis

## LAURENS LINDENBURG

Principal Scientist, Genmab

## THOMAS KRAFT

Principal Scientist, Hoffmann-La Roche

## ANDREW BUCHANAN

Principal Scientist, Biologics Engineering

## MIKHAIL KURAVSKIY

Principal Scientist, UCB

## ISABELLE SERMADIRAS

Associate Principal Scientist, AstraZeneca

## BERIT OLSEN KROGH

Senior Research Fellow, Lundbeck

## OWEN VICKERY

Associate Principal Scientist Computational Biologics Design, AstraZeneca

## MARINA FEDOROVA

Scientific Investigator, Cellular Technology, GSK

## SARAH HINDSON

Senior Scientist, GSK

## DAVID BROCKWELL

Professor, University of Leeds

## SOPHIA KARAGIANNIS

Professor of Translational Cancer Immunology and Immunotherapy, King's College London

## ALAIN WAGNER

Research Director, University of Strasbourg

## EEF DIRKSEN

Group Lead Extended Analytical Characterisation, Byondis

## ANNA HINE

Professor of Protein Engineering, Aston University

## ED TATE

GSK Chair of Chemical Biology, Imperial College London & Francis Crick Institute

## KNUD JØRGEN JENSEN

Professor, University of Copenhagen

## JÖRG WISCHHUSEN

Professor, University of Wuerzburg

## VINCENZO DE FILIPPIS

Associate Professor Biochemistry, University of Padova

## CHRISTOPHER SCOTT

Professor and Dean of Faculty, Queen's University Belfast

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

Book Now



## Day One | Proteins, Antibodies & ADCs Programme

08:15 **Oxford Global's Welcome Address**

08:25 **Opening Keynote Address & Fireside Chat With Keynote Speaker**

	NOVEL TOOLS & TECHNOLOGIES FOR DISPLAY OF PROTEINS & ANTIBODIES	ADC DESIGN, VALIDATION & OPTIMISATION TO ENHANCE THEIR THERAPEUTIC POTENTIAL	ANALYTICAL DEVELOPMENT: STABILITY & IN-DEPTH CHARACTERISATION METHODS FOR PROTEINS & ANTIBODIES	UPSTREAM DEVELOPMENT OF PROTEINS & ANTIBODIES: NOVEL STRATEGIES FOR CELL LINE DEVELOPMENT & EXPRESSION OPTIMISATION
09:25	<p><b>Track Keynote Address: Current State-Of-The-Art Of Biologics Discovery &amp; Development</b></p> <p>FRANCISCA WOLLERTON, Senior Director of Protein Engineering &amp; Novel Modalities, <b>AstraZeneca</b></p>	<p><b>Track Keynote Address: Generation Of Bispecific Antibody Conjugates</b></p> <p>JOHN DE KRUIF, Executive Vice President, Chief Technology Officer, <b>Merus</b></p>	<p><b>Track Keynote Address: Characterisation Of Biotherapeutics</b></p> <p>SARAH STUART, High Throughput Characterisation Team Leader, <b>GSK</b></p>	<p><b>Track Keynote Address: High-Throughput Screening For Biologics</b></p> <p>JENNY FITTING, Head of AAV and Protein Science, <b>Bayer AG</b></p>
09:50	<p><b>Mammalian And Phage Display For Discovery And Engineering Of Proteins And Antibodies For Therapeutic Purposes In Multiple Modalities</b></p> <p>BRYCE NELSON, Head of Protein and Antibody Engineering, <b>Orion Corporation</b></p>	<p><b>New Approaches For ADC Linker &amp; Payload Discovery</b></p> <p>ED TATE, GSK Chair of Chemical Biology, <b>Imperial College London &amp; Francis Crick Institute</b></p>	<p><b>In-Depth Characterisation Of ADCs In Preparation For Regulatory Approvals</b></p> <p>EEF DIRKSEN, Group Lead Extended Analytical Characterisation, <b>Byondis</b></p>	<p><b>Industry Presentation</b></p> <p>SPEAKER TBA</p>
10:15	<p><b>Corporate / Diamond Solution Provider Presentation</b></p> <p><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i></p>	<p><b>Corporate / Diamond Solution Provider Presentation</b></p> <p><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i></p>	<p><b>Corporate / Diamond Solution Provider Presentation</b></p> <p><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i></p>	<p><b>Corporate / Diamond Solution Provider Presentation</b></p> <p><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i></p>

### MORNING BREAK & REFRESHMENTS



1-2-1 Meetings x3



Poster Displays



Technology Showcase Presentations on the 'Visionary Voices' Stage



### CROSS-PROGRAMME ROUNDTABLES

10:40 - 11:40

**Roundtable 1: Improving Sustainable Chemistry Practices: Short Term Vs Long Term Solutions**

- What are the current opportunities to improve?
- Sustainable practices in pharma
- What are the technology leaps that could change the dynamic?

**Moderator:**  
LOUIS DIORAZIO, Senior Principal Scientist, New Modalities, **AstraZeneca**

**Roundtable 2: Patent Strategies During Development Of Biologics**

**Moderator:**  
JEAN GE, Patent Attorney, **Wolf Greenfield**

**Roundtable 3: Nasal Delivery Of Biologics**

- Delivery systems
- Modelling for delivery

**Moderator: (Reserved)** MARCO BECHERELLI, CMC Technical Leader Biologics, **Chiesi Pharmaceuticals**

*Moderator TBC*

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme



Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes



Advances in Immunotherapy & Immunology Programme



Vaccines Programme



Innovation & Collaboration Programme



Venue Information

**Book Now**

## Day One | Proteins, Antibodies & ADCs Programme

	<b>NOVEL TOOLS &amp; TECHNOLOGIES FOR DISPLAY OF PROTEINS &amp; ANTIBODIES</b>	<b>ADC DESIGN, VALIDATION &amp; OPTIMISATION TO ENHANCE THEIR THERAPEUTIC POTENTIAL</b>	<b>ANALYTICAL DEVELOPMENT: STABILITY &amp; IN-DEPTH CHARACTERISATION METHODS FOR PROTEINS &amp; ANTIBODIES</b>	<b>UPSTREAM DEVELOPMENT OF PROTEINS &amp; ANTIBODIES: NOVEL STRATEGIES FOR CELL LINE DEVELOPMENT &amp; EXPRESSION OPTIMISATION</b>
	<b>Sponsored Workshop</b>	<b>Sponsored Workshop</b>	<b>Sponsored Workshop</b>	<b>Sponsored Workshop</b>
11:40				
13:20 - 14:20	<b>LUNCH BREAK</b>			
	 1-2-1 Meetings x3		 Poster Displays	
	<b>THOUGHT-LEADERSHIP PANEL DISCUSSIONS</b>			
14:20	<p><b>Thought-Leadership Panel Discussion: The Role Of AI/Machine Learning In Biologics Drug Discovery</b></p> <ul style="list-style-type: none"> <li>• ML/Computational tools impacting antibody R&amp;D</li> <li>• Digital transformation</li> <li>• Benchmarking</li> <li>• AI in our daily jobs</li> </ul> <p><b>Moderator:</b> ANDREW BUCHANAN, Principal Scientist, Biologics Engineering, <b>AstraZeneca</b></p> <p><b>Panellist:</b> TALIP UCAR, Senior Director – AI Research, <b>AstraZeneca</b></p>	<p><b>Thought-Leadership Panel Discussion: TBC</b></p> <p>SPEAKER TBA</p>	<p><b>Thought-Leadership Panel Discussion: The Future Of Different Biologics Formats</b></p> <ul style="list-style-type: none"> <li>• Pros &amp; cons of different formats (antibodies, TCRs, peptides, multi-specifics)</li> <li>• Tailoring your drug for the right indication (size, half-life, potency)</li> </ul> <p>SPEAKER TBA</p>	<p><b>Thought-Leadership Panel Discussion: Propelling Upstream Development &amp; Market Expansion</b></p> <ul style="list-style-type: none"> <li>• Single-use technologies</li> <li>• Key growth factors</li> </ul> <p>SPEAKER TBA</p>
15:10	<p><b>On Cryo-Electron Microscopy Revolutionizing Rational Approaches In The Biologics Drug Discovery</b></p> <p>ALEXEY RAK, Head of Bio Structure and Biophysics, <b>Sanofi</b></p>	<p><b>High-Throughput Characterisation Methods For ADCs</b></p> <p>SARAH HINDSON, Senior Scientist, <b>GSK</b></p>	<p><b>Applications Of HDX-MS In The Study Of Protein-Antibody Interaction</b></p> <p>VINCENZO DE FILIPPIS, Associate Professor Biochemistry, <b>University of Padova</b></p>	<p><b>Applying ML To Protein Expression Challenges</b></p> <p>ERIK VERNET, Senior Director, External Partnerships &amp; Emerging Technologies, <b>Novo Nordisk</b></p>
15:35	<p><b>How Do Complex Antibody Formats Affect Their Non-Specific Pharmacokinetic Properties</b></p> <ul style="list-style-type: none"> <li>• We systematically evaluated the impact of antibody complex format on their pharmacokinetic properties using different in vitro assays and in vivo studies</li> <li>• We found a clear structure-PK relationship and mechanistically identified the major underlying biological mechanisms</li> </ul> <p>THOMAS KRAFT, Principal Scientist, <b>Hoffmann-La Roche</b></p>	<p><b>Antibody Drug Conjugates To Take Account Of The Tumour Microenvironment</b></p> <p>SOPHIA KARAGIANNIS, Professor of Translational Cancer Immunology and Immunotherapy, <b>King's College London</b></p>	<p><b>Industry Presentation</b></p> <p>SPEAKER TBA</p>	<p><b>Customisable Protein Expression</b></p> <p>MARINA FEDOROVA, Scientific Investigator, Cellular Technology, <b>GSK</b></p>

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

Book Now

## Day One | Proteins, Antibodies & ADCs Programme

NOVEL TOOLS & TECHNOLOGIES FOR DISPLAY OF PROTEINS & ANTIBODIES

ADC DESIGN, VALIDATION & OPTIMISATION TO ENHANCE THEIR THERAPEUTIC POTENTIAL

ANALYTICAL DEVELOPMENT: STABILITY & IN-DEPTH CHARACTERISATION METHODS FOR PROTEINS & ANTIBODIES

UPSTREAM DEVELOPMENT OF PROTEINS & ANTIBODIES: NOVEL STRATEGIES FOR CELL LINE DEVELOPMENT & EXPRESSION OPTIMISATION

### AFTERNOON BREAK & REFRESHMENTS



1-2-1 Meetings x3



Poster Displays



Fireside Chats on the 'Visionary Voices' Stage



#### Deep Mutational Scanning Assay With Yeast Display

LAURENS LINDENBURG, Principal Scientist, **Genmab**

#### New Chemical Approaches To Antibody Conjugations

KNUD JØRGEN JENSEN, Professor, **University of Copenhagen**

#### In-Depth Characterisation Of ADCs In Preparation For Regulatory Approvals

ALAIN WAGNER, Research Director, **University of Strasbourg**

#### High Throughput Cell Screening For Antibody Discovery

ALAIN WAGNER, Research Director, **University of Strasbourg**

#### New Formats For Reagent Antibodies

ANNA HINE, Professor of Protein Engineering, **Aston University**

#### Roundtable Discussion: Addressing ADC Chemistry Challenges

- What is the best way to develop site-specific ADCs?
- Addressing solubility issues

**Moderator:** SOPHIA KARAGIANNIS, Professor of Translational Cancer Immunology and Immunotherapy, **King's College London**

#### Roundtable Discussion: Characterisation Method Verification & Validation

- Analytical characterisation methods in regulatory filings for protein-based products?
- How is a characterisation method 'scientifically sound' and 'fit for purpose'?
- Do you assess validation parameters for your characterisation methods, i.e. linearity, sensitivity, precision, etc.?
- Have you ever had regulatory feedback on the panel of characterisation methods used and/or the characterisation data included in a regulatory filing?
- Have you undertaken any efforts to use orthogonal methods to verify spectroscopic data related to protein higher order structure?

**Moderator:** EEF DIRKSEN, Group Lead Extended Analytical Characterisation, **Byondis**

#### Roundtable Discussion: Maximizing Protein Production Workflows: R&D With The End-In-Mind

- Increasing the productivity from early project to development
- Investments needed to increase the productivity
- Differences for antibodies and proteins in the timelines

**Moderator:** JENNY FITTING, Head of AAV and Protein Science, **Bayer AG**

#### Targeting Ion Channels With Antibodies & Antibody Fusion Molecules

ANEESH KARATT VELLATT, Chief Scientific Officer, **Maxion Therapeutics**

### ROUNDTABLE DISCUSSIONS & REGULATORY INSIGHT

#### Roundtable Discussion & Regulatory Insight: IP Insights On ADCs

**Moderator:** JEAN GE, Patent Attorney, **Wolf Greenfield**

#### Roundtable Discussion & Regulatory Insight: TBA

**Moderator TBA**

#### Roundtable Discussion & Regulatory Insight: TBA

**Moderator TBA**

Grab a drink & make your way to the Visionary Voices Stage for the end of day summaries

### CLOSE OF DAY ONE

Networking Drinks & Themed Bar Areas (Proteins, Antibodies & ADCs, Peptides, Oligonucleotides, Immunotherapy, Vaccines)

Canapés Reception

End of Day Summary x3

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme



Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes



Advances in Immunotherapy & Immunology Programme



Vaccines Programme



Innovation & Collaboration Programme



Venue Information

Book Now



## Day Two | Proteins, Antibodies & ADCs Programme

08:30

*Come & join us for a refreshing start of the day*

09:00

### Keynote Address: The Journey From TCR Discovery Through To Approval

TRISTAN VAUGHAN, Vice President of Protein Engineering, **Immunocore**

09:25

ANTIBODY DISCOVERY & ENGINEERING	NEW FORMATS: CYTOKINES, IMMUNOCYTOKINES & NOVEL THERAPEUTIC FORMATS	EMERGING ANALYTIC TECHNIQUES, DEVELOPABILITY & QUALITY CONTROL SYSTEMS	DOWNSTREAM DEVELOPMENT FOR ANTIBODIES AND FC CONTAINING MOLECULES
<b>Track Keynote Address: Multispecifics High-Throughput Engineering Platforms</b>  MARTA AMARAL, Head of High-Throughput Protein Engineering, <b>Sanofi</b>	<b>Track Keynote Address: Antibody-Based Cytokine Mimetics</b>  STEFAN ZIELONKA, Director and Head of Antibody Discovery and Protein Engineering, <b>Merck Healthcare KGaA</b>	<b>Track Keynote Address: Characterisation Of Biologics Through Functional Assays</b>  KELLY LOYET, Distinguished Scientist, <b>Genentech</b>	<b>Track Keynote Address</b>  SPEAKER TBA
<b>Making Monoclonal Antibodies More Tolerant Of Viral Evolution</b>  SIMON HUFTON, Section Head Molecular Immunology, Division of Biotherapeutics, <b>National Institute for Biological Standards and Control (NIBSC)</b>	<b>New Therapeutic Formats: Nanofitins</b>  MATHIEU CINIER, Scientific Director, <b>Afflogic</b>	<b>Change In Immunoassay Method From Phase 1 To Phase 3 For Release Purpose – A Case Study</b>  VINCENT DEWAR, Associate Director, <b>GSK</b>	<b>Industry Presentation</b>  SPEAKER TBA
<b>Solution Provider Presentation</b>  	<b>Platinum/Gold Solution Provider Presentation</b>  For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a>	<b>Platinum/Gold Solution Provider Presentation</b>  For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a>	<b>Platinum/Gold Solution Provider Presentation</b>  For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a>

09:50

10:15

10:40

### MORNING BREAK & REFRESHMENTS



1-2-1 Meetings x3



Poster Displays



Fireside Chats on the 'Visionary Voices' Stage



Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme



Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes



Advances in Immunotherapy & Immuno-Oncology Programme



Vaccines Programme





Innovation & Collaboration Programme



Venue Information

Book Now

**Day Two | Proteins, Antibodies & ADCs Programme**

	<b>ANTIBODY DISCOVERY &amp; ENGINEERING</b>	<b>NEW FORMATS: CYTOKINES, IMMUNOCYTOKINES &amp; NOVEL THERAPEUTIC FORMATS</b>	<b>EMERGING ANALYTIC TECHNIQUES, DEVELOPABILITY &amp; QUALITY CONTROL SYSTEMS</b>	<b>DOWNSTREAM DEVELOPMENT FOR ANTIBODIES AND FC CONTAINING MOLECULES</b>
11:40	<p><b>Format Explorations For Sweeping Of Highly Abundant Targets</b></p> <ul style="list-style-type: none"> <li>•The pathogenicity of autoreactive antibodies has been demonstrated for many autoimmune diseases and the isotype/subclass profile can potentially influence the disease pathophysiology</li> <li>•IgA autoantibodies are increasingly recognized in different autoimmune indications</li> <li>•The development of anti-IgA monoclonal antibodies can actively remove IgA from the circulation and block binding of IgA to its main Fc receptor FcαRI</li> <li>•Given the abundance of IgA in human serum (1-3 mg/mL), both Fab and Fc engineering were optimized to design a monoclonal antibody with the desired properties</li> </ul> <p>KAREN SILENCE, Head Preclinical Product Development, <b>ArgenX</b></p>	<p><b>Novel Target Identification And Validation Approaches</b></p> <ul style="list-style-type: none"> <li>•Big Data analytics</li> <li>•Genomic screening</li> </ul> <p>LAURA STARKIE, Director, <b>UCB</b></p>	<p><b>Repertoire Deep Mining Improves Functionality Of Antibodies With Unique Properties</b></p> <p>(Reserved) NIKOLAJ DIETRICH, Associate Scientific Director, Therapeutic Innovation Biologic Drug Design, <b>Symphogen</b></p>	<p><b>Industry Presentation</b></p> <p>SPEAKER TBA</p>
12:05	<p><b>Sponsored Workshop</b></p> 	<p><b>Platinum/Gold Solution Provider Presentation</b></p> <p><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i></p>	<p><b>Platinum/Gold Solution Provider Presentation</b></p> <p><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i></p>	<p><b>Platinum/Gold Solution Provider Presentation</b></p> <p><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i></p>
12:30	<p><b>Generation And Engineering Of Cattle Derived Ultralong CDR-H3 Antibodies</b></p> <p>SIMON KRAH, Associate Director, Protein Engineering &amp; Antibody Technologies, <b>Merck KGaA</b></p>	<p><b>Exploring The Therapeutic Applications Of IGE And IGE Derived Antibodies</b></p> <p>KEVIN FITZGERALD, Chief Scientific Officer, <b>EpsilonGen</b></p>	<p><b>Multi-Attribute Methods To Inform Developability</b></p> <p>EMMA GRANT, Senior Scientist, <b>Immunocore</b></p>	<p><b>Industry Presentation</b></p> <p>SPEAKER TBA</p>
12:55 - 13:55	<b>LUNCH BREAK</b>			
	 <p>1-2-1 Meetings x3</p> 	 <p>Poster Displays</p> 		
13:55	<p><b>Solution Provider Presentation</b></p> 	<p><b>Silver And Above Solution Provider Presentation</b></p> <p><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i></p>	<p><b>Solution Provider Presentation</b></p> 	<p><b>Silver And Above Solution Provider Presentation</b></p> <p><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i></p>

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme



Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes



Advances in Immunotherapy & Immuno-Oncology Programme



Vaccines Programme













Innovation & Collaboration Programme



Venue Information

**Book Now**

## Day Two | Proteins, Antibodies & ADCs Programme

ANTIBODY DISCOVERY & ENGINEERING	NEW FORMATS: CYTOKINES, IMMUNOCYTOKINES & NOVEL THERAPEUTIC FORMATS	EMERGING ANALYTIC TECHNIQUES, DEVELOPABILITY & QUALITY CONTROL SYSTEMS	DOWNSTREAM DEVELOPMENT FOR ANTIBODIES AND FC CONTAINING MOLECULES
<p><b>Panel Discussion: What Is The Next Game Changer In Antibody Engineering?</b></p> <ul style="list-style-type: none"> <li>• De novo design novel antibody binders</li> <li>• Benchmarking the impact of AI/ML in biologics discovery and optimisation for pharma</li> <li>• Innovative discovery methods</li> <li>• Multi-specifics: how should we approach different formats?</li> </ul> <p>14:20</p> <p><b>Moderator:</b> KAREN SILENCE, Head Preclinical Product Development, <b>ArgenX</b></p> <p><b>Panellists:</b>            BERIT OLSEN KROGH, Senior Research Fellow, <b>Lundbeck</b>            ANDREW BUCHANAN, Principal Scientist, Biologics Engineering, <b>AstraZeneca</b></p>	<p><b>Development Of Novel Antibody-Targeted Complex Medicines</b></p> <p>CHRISTOPHER SCOTT, Professor and Dean of Faculty, <b>Queen's University Belfast</b></p> <p><b>Exploiting &amp; Targeting Mechanisms</b></p> <p>JÖRG WISCHHUSEN, Professor, <b>University of Wuerzburg</b></p>	<p><b>Panel Discussion: Analytical Development Of Biologics: What's Next For The Future?</b></p> <ul style="list-style-type: none"> <li>• Multi-attribute methods &amp; overcoming challenges with their regulatory guidelines</li> <li>• Condensing different methods into one &amp; demonstrating comparability to original methods</li> </ul> <p><b>Moderator:</b> EMMA GRANT, Senior Scientist, Immunocore</p> <p><b>Panellists:</b>            KELLY LOYET, Distinguished Scientist, <b>Genentech</b>            ALAIN WAGNER, Research Director, <b>University of Strasbourg</b>            VINCENZO DE FILIPPIS, Associate Professor Biochemistry, <b>University of Padova</b></p>	<p><b>Panel Discussion: Emerging Technologies And Trends In Downstream Processing</b></p> <ul style="list-style-type: none"> <li>• Novel purification methods</li> <li>• Single-use technologies</li> <li>• Automation &amp; robotics</li> </ul> <p>SPEAKER TBA</p>
<p><b>Solution Provider Presentation</b></p> <p>15:10</p> 	<p><b>Silver And Above Solution Provider Presentation</b></p> <p><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i></p>	<p><b>Solution Provider Presentation</b></p> <p>15:10</p> 	<p><b>Silver And Above Solution Provider Presentation</b></p> <p><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i></p>
AFTERNOON BREAK & REFRESHMENTS			
<p>15:35</p>  <p>1-2-1 Meetings x3</p> 	<p>15:35</p>  <p>Poster Displays</p> 	<p>15:35</p>  <p>Fireside Chats on the 'Visionary Voices' Stage</p> 	
<p><b>Solution Provider Presentation</b></p> <p>16:35</p> 	<p><b>Silver And Above Solution Provider Presentation</b></p> <p><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i></p>	<p><b>Solution Provider Presentation</b></p> <p>16:35</p> 	<p><b>Silver And Above Solution Provider Presentation</b></p> <p><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i></p>

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

Book Now

## Day Two | Proteins, Antibodies & ADCs Programme

	ANTIBODY DISCOVERY & ENGINEERING	NEW FORMATS: CYTOKINES, IMMUNOCYTOKINES & NOVEL THERAPEUTIC FORMATS	EMERGING ANALYTIC TECHNIQUES, DEVELOPABILITY & QUALITY CONTROL SYSTEMS	DOWNSTREAM DEVELOPMENT FOR ANTIBODIES AND FC CONTAINING MOLECULES
17:00	<p><b>Roundtable Discussion: Antibody Discovery Against Complex Membrane Protein Targets</b></p> <ul style="list-style-type: none"> <li>Solving the antigen problem</li> <li>New screening technologies</li> <li>New target classes within the space e.g. transporters</li> </ul> <p><b>Moderator:</b> ANEESH KARATT VELLATT, Chief Scientific Officer, Maxion Therapeutics</p>	<p><b>Panel Discussion: New Immunocytokine Formats</b></p> <ul style="list-style-type: none"> <li>Targeting TAA vs immune cells</li> <li>Immunocytokines for non-cancer indications</li> <li>Tolerance</li> </ul> <p><b>Moderator:</b> <i>(Invited)</i> STEFAN ZIELONKA, Director and Head of Antibody Discovery and Protein Engineering, Merck Healthcare KGaA</p> <p><b>Panellist:</b> JÖRG WISCHHUSEN, Professor, University of Wuerzburg</p>	<p><b>Industry Workshop: Developability Assessment With Novel Strategies &amp; Techniques In 2025 &amp; Beyond</b></p> <p><b>Presentation 1: Developability Assessment For Biotherapeutics</b></p> <p>PAUL WASSMANN, Senior Principal Scientist, Novartis</p> <p><b>Presentation 2: Rationalising MABs Developability Testing</b></p> <p>DAVID BROCKWELL, Professor, University of Leeds</p> <p><b>Panel Discussion: Novel Strategies &amp; Techniques For Developability Assessments</b></p> <ul style="list-style-type: none"> <li>Accelerating the developability of molecules</li> <li>Automation</li> <li>Using AI</li> <li>Developability for nextgen formats (e.g. bispecifics, mABs, fusion proteins)</li> </ul> <p><b>Panellists:</b>            PAUL WASSMANN, Senior Principal Scientist, Novartis            DAVID BROCKWELL, Professor, University of Leeds  <i>(Reserved)</i> ISABELLE SERMADIRAS, Associate Principal Scientist, AstraZeneca</p>	<p><b>Industry Workshop: Innovations In Downstream Process Development For Proteins &amp; Antibodies</b></p>
17:25	<p><b>Allosteric Inhibition Of A Protease Target By An Antibody</b></p> <p>HENRY MAUN, Associate Director, Genentech</p>			
17:50	<p><b>Modular Design Of Bi- And Multi-Specific Knob Domain Fusions</b></p> <p>MIKHAIL KURAVSKIY, Principal Scientist, UCB</p>			
18:15	<p><i>Grab a drink &amp; make your way to the Visionary Voices Stage for the end of day summaries</i></p>			
<p><b>CLOSE OF DAY TWO</b></p>				
18:20	<p>Poster Presentation Awards Ceremony</p> <p>Networking Drinks</p> <p>End of Day Summaries x3</p>			

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme



Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes



Advances in Immunotherapy & Immuno-Oncology Programme



Vaccines Programme



Innovation & Collaboration Programme



Venue Information

[Book Now](#)

## Day Three | Proteins, Antibodies & ADCs Programme

08:30

Come & join us for a refreshing start of the day

Welcome

### AI/ML-GUIDED PROTEIN & ANTIBODY ENGINEERING

### NEXTGEN MULTI-SPECIFICS, CELL ENGAGERS & OTHER NEW MODALITIES

### NOVEL STRATEGIES FOR CLINICAL DEVELOPMENT

### PROTEIN PROCESS DEVELOPMENT: PROTEIN PURIFICATION & RECOMBINANT PROTEIN PRODUCTION

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

Book Now

**Track Keynote Address: Accelerating Antibody Design And Optimisation In The Era Of Generative AI**

**Track Keynote Address: Development Of Novel Multi-Specific Immune Engager Therapeutics To Treat Cancer**

**Track Keynote Address: Accelerating Preclinical CMC Through Innovation & Optimisation**

**Track Keynote Address: High-Throughput Methodologies For Antigen Generation**

TALIP UCAR, Senior Director – AI Research, **AstraZeneca**

MICHAEL DYSON, Vice President, Antibody Discovery and Engineering, **Ichnos Glenmark Innovation**

RICK HIBBERT, Vice President & Head of CMC Science & Technologies, **Genmab**

MAJA FIRZUK, HT Expression Team Leader, **GSK**

**Gold And Above Solution Provider Presentation**

**Gold And Above Solution Provider Presentation**

**Gold And Above Solution Provider Presentation**

**Gold And Above Solution Provider Presentation**

For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

**AI/ML For Structure-Based De Novo Antibody Design**

**The Making Of Active And Developable Multiclomics® Antibodies**

**First In Class TS-mRNA Binder To Abolish Aberrant Protein Expression; Clinical Development Program**

**High-Throughput Platform For The Generation Of Biologics**


VLADIMIR GLIGORIJEVIC, Senior Director of AI/ML, **Genentech**



JOHN DE KRUIF, Executive Vice President, Chief Technology Officer, **Merus**

SONIA MACIA, Chief Medical Officer, **Aromics Therapeutics**

MATTHEW BURRELL, Associate Director, **AstraZeneca**

### MORNING BREAK & REFRESHMENTS

 1-2-1 Meetings x3 

 Poster Displays 

 Technology Showcases on the 'Visionary Voices' Stage 

**Panel Discussion: Women In NextGen BioMed**

- Breaking traditional barriers in STEM
- Women's newest contributions to biomedicine
- Challenges in breaking through the glass ceiling of the traditional biomedicine field

**Moderator:** AMITA VAIDYA, Principal Scientist, **Sanofi**

**Gold And Above Solution Provider Presentation**

**Gold And Above Solution Provider Presentation**

**Silver And Above Solution Provider Presentation**

**Silver And Above Solution Provider Presentation**

**QUANTUM SI**

**IC50 SAGEN**  
CELL FACTORY




For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

11:15



## Day Three | Proteins, Antibodies & ADCs Programme

	AI/ML-GUIDED PROTEIN & ANTIBODY ENGINEERING	NEXTGEN MULTI-SPECIFICS, CELL ENGAGERS & OTHER NEW MODALITIES	NOVEL STRATEGIES FOR CLINICAL DEVELOPMENT	PROTEIN PROCESS DEVELOPMENT: PROTEIN PURIFICATION & RECOMBINANT PROTEIN PRODUCTION
11:40	<p><b>AI/ML-Guided Antibody Engineering: NANOBODY®</b></p> <p>NORBERT FURTMANN, Head of AI Innovation, <b>Sanofi</b></p>	<p><b>Beyond Antibodies: A Simplified Protein Modality For Targeting Solid Tumours</b></p> <ul style="list-style-type: none"> <li>•Our technology is designed to rapidly generate bispecific therapeutics with various novel and existing moieties such as nanobodies, scFvs, and non-antibody domains in a “LEGO”-like manner to generate TCEs</li> <li>•The TCEs have very high safety profiles compared to conventional biologics and low pro-inflammatory cytokines</li> <li>•In vivo efficacy has been demonstrated in NSCLC mouse models</li> </ul> <p>RAJIKA PERERA, Chief Executive Officer, <b>Poseidon LLC</b></p>	<p><b>Immunogenicity Assessment From Pre-Clinical To Clinical</b></p> <p>RITA MARTELLO, Scientific Director, NBE DMPK Lead &amp; Head of External NBE DMPK Leads Clinical Activities, <b>Merck KGaA</b></p>	<p><b>To Be Confirmed</b></p> <p>(Reserved) SANDEEP TALAPATRA, Protein Science Group Lead, Protein &amp; Cellular Sciences, <b>GSK</b></p>
12:05	<p><b>Bronze And Above Solution Provider Presentation</b></p> <p><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i></p>	<p><b>Solution Provider Presentation</b></p> 	<p><b>Bronze And Above Solution Provider Presentation</b></p> <p><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i></p>	<p><b>Bronze And Above Solution Provider Presentation</b></p> <p><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i></p>
12:30	<p><b>Roundtable: Internalisation Of Antibody Therapeutics Into Dendritic Cells As A Risk Factor For Immunogenicity</b></p> <ul style="list-style-type: none"> <li>•High levels of antibody internalisation into dendritic cells have been linked to an increased risk of immunogenicity</li> <li>•What is the impact of target mediated and target independent internalisation?</li> <li>•How can such risk be assessed pre-clinically and potentially mitigated?</li> <li>•Can half-life extending mutations that increase the affinity to FcRn lower that risk?</li> </ul> <p><b>Co-Moderators:</b> THOMAS KRAFT, Principal Scientist, <b>Hoffmann-La Roche</b>; TIMOTHY HICKLING, Investigative Safety and Immunotoxicity Chapter Lead, <b>Hoffmann-La Roche</b></p>	<p><b>Bispecific Gamma Delta T-Cell Engagers For Cancer Immuno Therapy</b></p> <p>HANS VAN DER VLIET, Chief Scientific Officer, <b>LAVA Therapeutics</b></p>	<p><b>Overview Of Chiesi's Clinical Development Efforts</b></p> <p>(Reserved) MARCO BECHERELLI, CMC Technical Leader Biologics, <b>Chiesi Pharmaceuticals</b></p>	<p><b>Industry Presentation</b></p>
12:55 - 13:55	<b>LUNCH BREAK</b>			
	 <p>1-2-1 Meetings x3</p> 	 <p>Poster Displays</p> 		

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme



Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes



Advances in Immunotherapy & Immuno-Oncology Programme



Vaccines Programme




Innovation & Collaboration Programme



Venue Information

[Book Now](#)

**Day Three | Proteins, Antibodies & ADCs Programme**

AI/ML-GUIDED PROTEIN & ANTIBODY ENGINEERING	NEXTGEN MULTI-SPECIFICS, CELL ENGAGERS & OTHER NEW MODALITIES	NOVEL STRATEGIES FOR CLINICAL DEVELOPMENT	PROTEIN PROCESS DEVELOPMENT: PROTEIN PURIFICATION & RECOMBINANT PROTEIN PRODUCTION
<p><b>Panel Discussion: Using Generative AI For Biologics Drug Design</b></p> <ul style="list-style-type: none"> <li>• Prediction of structures of antibodies and multi-specifics based on generativeAI models</li> <li>• AI-based developability assessment</li> </ul> <p>13:55</p> <p><b>Moderator:</b> VLADIMIR GLIGORIJEVIC, Senior Director of AI/ML, Genentech  <b>Panellists:</b>            OWEN VICKERY, Associate Principal Scientist Computational Biologics Design, AstraZeneca            TALIP UCAR, Senior Director – AI Research, AstraZeneca</p>	<p><b>Multi-Specific Formats &amp; Binders Beyond Bispecifics</b></p> <p>DARKO SKEGRO, Associate Director- Group Head Biotherapeutic Engineering and Conjugation, <b>Novartis</b></p> <p><b>Combination Approaches To Expand The Efficacy Of Current Immune Checkpoint Modulators</b></p> <p>(Reserved) BISHNU NAYAK, Senior Director, <b>NeoLogics Bioscience</b></p>	<p><b>Panel Discussion: Designing Effective Clinical Trials For Biologics</b></p> <ul style="list-style-type: none"> <li>• Best practices in designing Phase I, II, and III trials for biologics</li> <li>• Strategies for incorporating biomarkers and personalised medicine into trial design</li> <li>• Challenges and solutions in trial design for rare diseases and orphan biologics</li> <li>• Regulatory pathways &amp; approval processes</li> </ul>	<p><b>Industry Presentation</b></p> <p><b>Industry Presentation</b></p>
<p><b>Bronze And Above Solution Provider Presentation</b></p> <p>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></p>	<p><b>Solution Provider Presentation</b></p> 	<p><b>Bronze And Above Solution Provider Presentation</b></p> <p>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></p>	<p><b>Bronze And Above Solution Provider Presentation</b></p> <p>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></p>
<p><b>New Computational Tools To Predict mAB And Peptide Affinity</b></p> <p>15:10</p> <p>ANDREW BUCHANAN, Principal Scientist, Biologics Engineering, <b>AstraZeneca</b></p>	<p><b>TCR-Based Therapeutics Against Cancer</b></p> <ul style="list-style-type: none"> <li>• OptiMus transgenic mouse platform for TCR discovery</li> <li>• Computational strategies for TCR selection</li> <li>• Oncology program discovery</li> </ul> <p>AMY LI, Director, Drug Discovery, <b>T-Therapeutics</b></p>	<p><b>Insights Into Successful Industry Clinical Collaborations</b></p> <ul style="list-style-type: none"> <li>• Why do we establish clinical collaborations with external companies?</li> <li>• Industry Clinical Collaborations (ICC) at Roche</li> <li>• Drugs combinations in ICC</li> <li>• Successes &amp; challenges with commercial drugs &amp; novel / novel combinations</li> </ul> <p>DENISE STECKEL, Head of Clinical Collaborations Development, <b>Genentech</b></p>	<p><b>Industry Presentation</b></p>

15:35 **AFTERNOON BREAK & REFRESHMENTS**

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

**Book Now**

Day Three | Proteins, Antibodies & ADCs Programme

	AI/ML-GUIDED PROTEIN & ANTIBODY ENGINEERING	NEXTGEN MULTI-SPECIFICS, CELL ENGAGERS & OTHER NEW MODALITIES	NOVEL STRATEGIES FOR CLINICAL DEVELOPMENT	PROTEIN PROCESS DEVELOPMENT: PROTEIN PURIFICATION & RECOMBINANT PROTEIN PRODUCTION
15:50	<p><b>Antibody Affinity Maturation – Using AI-Based Tools To Bidirectional Understand The Past And Enable The Future</b></p> <p>BERIT OLSEN KROGH, Senior Research Fellow, <b>Lundbeck</b></p>	<p><b>Panel Discussion: Mixed Modalities: Addressing The Challenges &amp; Opportunities To Drug The Undruggable</b></p> <ul style="list-style-type: none"> <li>• Design of the molecules•</li> <li>• From pre-clinical to clinical</li> <li>• Going beyond T cell engagers</li> </ul>	<p><b>Industry Presentation</b></p>	<p><b>Panel Discussion: The Future Of Purified Antigens</b></p> <ul style="list-style-type: none"> <li>• Can we replace experiments with predictions?</li> <li>• How far can we go with miniaturisation?</li> </ul>
16:15	<p><b>In Silico Developability For Biologics</b></p> <p>ISABELLE SERMADIRAS, Associate Principal Scientist, <b>AstraZeneca</b></p>	<p><b>Moderator:</b> DARKO SKEGRO, Associate Director- Group Head Biotherapeutic Engineering and Conjugation, <b>Novartis</b></p> <p><b>Panellists:</b></p> <p>AMY LI, Director, Drug Discovery, <b>T-Therapeutics</b></p> <p>HANS VAN DER VLIET, Chief Scientific Officer, <b>LAVA Therapeutics</b></p> <p><i>(Reserved)</i></p> <p>BISHNU NAYAK, Senior Director, <b>NeoLogics Bioscience</b></p>	<p><b>Industry Presentation</b></p>	<p><b>Moderator:</b> MAJA FIR CZUK, HT Expression Team Leader, <b>GSK</b></p>
16:40	<p><b>Optimising Immunogenicity Risk By Design</b></p> <p>TIMOTHY HICKLING, Investigative Safety and Immunossafety Chapter Lead, <b>Hoffmann-La Roche</b></p>	<p><b>Target-Guided Site-Specific Delivery Of A First-In-Class soloMER Biologic For Immune-Mediated Inflammatory Diseases</b></p> <p>OBINNA UBAH, Principal Scientist and Future Leaders Fellow, <b>Elasmogen</b></p>	<p><b>Industry Presentation</b></p>	<p><b>Industry Presentation</b></p>
17:05	<p><b>Applying Active Learning To Antibody Design</b></p> <p>OWEN VICKERY, Associate Principal Scientist Computational Biologics Design, <b>AstraZeneca</b></p>	<p><b>ATOR-4066: A Next-Generation CD40xCEACAM5 Agonistic Neo-X-Prime bsAb</b></p> <p>PETER ELLMARK, Chief Scientific Officer, <b>Alligator Bioscience</b></p>	<p><b>Industry Presentation</b></p>	<p><b>Industry Presentation</b></p>
17:30	<b>End of Conference</b>			

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme



Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes



Advances in Immunotherapy & Immuno-Oncology Programme



Vaccines Programme




Innovation & Collaboration Programme



Venue Information

[Book Now](#)



## Peptides Programme Overviews

Our Peptides programme brings together key experts in peptide chemistry and therapeutic development. With the latest technological advancements pushing the industry forward, join us in London to network, debate and discuss the pressing challenges & future opportunities.



## Oligonucleotides Programme Overviews

Join key opinion leaders bringing about a new era of innovation in this field. Presentations will be covering computational approaches, methods & tools to oligonucleotide CMC as well as analytical control strategies for oligos.



## Sustainability in Biologics & Tides Programme Overviews

Our Sustainability in Biologics & Tides tracks focus on a crucial and rapidly growing field, offering valuable insights into fostering sustainable innovation throughout biologics & tides research and development. The conference will explore sustainable synthesis approaches, green manufacturing practices, and eco-friendly supply chain processes.

**Formal and informal meeting opportunities** offer delegates the chance to discuss key solutions with leading service providers:

- Peptide Chemistry
- Peptide Design
- Peptide Therapeutics
- Medicinal Chemistry
- Oligo Synthesis
- Oligo Conjugation
- Oligo Modification
- Oligo Purification
- Green Chemistry
- Sustainability
- Organic Chemistry
- Process Chemistry

**VPs, Directors & Senior Managers** from leading pharma & biotech companies and research institutions in the following fields & more:

- Peptide Synthesis
- Peptide Analysis
- Peptide Sequencing
- Peptide Modifications
- Oligo Purification
- Mass Identification
- Stability Testing
- DNA & RNA Oligos
- Raw Materials
- Green Production
- Sustainable Engineering

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immun-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

Book Now



# Confirmed Speakers

KEY SPEAKERS



Day One | 09:25

Using Reinforcement Learning For Peptide Drug Discovery  
**IMMANUEL LERNER**, Chief Executive Officer, Pepticom



Day Two | 09:25

Cyclic Structured RNA Therapeutics  
**SUDHIR AGRAWAL**, Founder & President ARNAY Sciences, UMass Chan Medical School



Day One | 17:00

Solving Delivery To Build The Future Of RNA Therapies  
**REETA DASWANI**, Senior Scientist, Sixfold Bio



Day Two | 09:25

Drug Substance Manufacturing For Oncology Products  
**WILL NESBIT**, Director of Process Chemistry & CMC, Bicycle Therapeutics



Day Two | 11:40

Novel Linkers For The Synthesis Of Oligonucleotide Conjugates  
**SRITAMA BOSE**, Head of Chemistry Research & Innovation, NATA

## PEPTIDES SPEAKERS

### IMMANUEL LERNER

Chief Executive Officer, Pepticom

### JOËL RICHARD

Chief Development Officer, Enterome

### PETE GOUGH

Chief Scientific Officer, Nimble Therapeutics

### NAZNEEN DEWJI

Founder & Chief Executive Officer, Cenna Biosciences

### ALASTAIR LAWSON

Vice President and Immunology Fellow, UCB

### MALIN LEMURELL

Executive Director & Head of Medicinal Chemistry CVRM Biopharmaceuticals R&D, AstraZeneca

### WILL NESBIT

Director of Process Chemistry & CMC, Bicycle Therapeutics

### STEPHEN MILLER

Principal Scientist, Genentech

### LEONARDO DE MARIA

Principal Scientist, AstraZeneca

### JÁNOS KODRA

Principal Scientist, Novo Nordisk

### MARIA FAWAZ

Associate Principal Scientist, Merck & Co., Inc.

### MATTIAS MALM

Senior Research Scientist, Ferring Pharmaceuticals

### DAVID CRAIK

Director, Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science

### JUTTA EICHLER

Professor of Medicinal Chemistry, University of Erlangen-Nurnberg

### IAN HAMLEY

Professor of Physical Chemistry, University of Reading

### ANDREW JAMIESON

Professor of Chemical Biology, University of Glasgow

### MARC VENDRELL

Professor, University of Edinburgh

### GEORGIOS SKRETAS

Director, Institute for Bio-Innovation Biomedical Sciences Research Center "Alexander Fleming"

### CHRISTOPHER COXON

Senior Lecturer Medicinal Chemistry, The University of Edinburgh

### MICHAL SHOSHAN

Group Leader, University of Zurich & Founder, metaLead

### KOMAL KEDIA

Associate Principal Scientist, Merck & Co. Inc.

## OLIGONUCLEOTIDE SPEAKERS

### SUDHIR AGRAWAL

Founder & President, & Affiliate Professor, ARNAY Sciences & UMass Chan Medical School

### DAVID EVANS

Chief Scientific Officer, Sirnaomics

### CHRISTOPHER HART

Chief Executive Officer, Creyon Bio

### MORTEN LINDOW

RNAHub Founder & Mission Lead, F. Hoffmann-La Roche Ltd

### LUCAS BETHGE

Vice President & Group Leader of Oligonucleotide Chemistry, Silence Therapeutics

### GAL GUR

Vice President Business Development, Anima Biotech

### JIM WETERINGS

Vice President Research, Sirnaomics

### WEN-HSUAN CHANG

Associate Vice President Discovery and Early Development, AcuraStem

### DAN SWERDLOW

Senior Director Discovery Medicine, GSK

### SAUL MARTINEZ MONTERO

Senior Director RNA Therapeutics, Dyne Therapeutics

### FELIX SCHUMACHER

Program Leader Targeted Therapeutics, F. Hoffmann-La Roche Ltd

### STEVE HOOD

Senior Director, Oligonucleotide ADME Strategy, GSK

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immunology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

Book Now



# Confirmed Speakers

KEY SPEAKERS



Day Three | 15:10

Case Study From AstraZeneca: Peptide Therapeutics

**MALIN LEMURELL**, Executive Director & Head of Medicinal Chemistry CVRM Biopharmaceuticals R&D, AstraZeneca



Day Three | 09:00

siRNA To Treat Oncology Indications

**DAVID EVANS**, Chief Scientific Officer, Sirnaomics



Day Three | 16:15

Delivery Of Nucleic Acids To The Brain

**IJEOMA UCHEGBU**, Professor of Pharmaceutical Nanoscience, University College London



Day Three | 11:40

Developing Oral Peptide Therapeutics At The Speed Of Light

**PETE GOUGH**, Chief Scientific Officer, Nimble Therapeutics



Day Three | 09:50

Utilizing the iNeuroTx Platform For Patient-Based Therapeutics

**WEN-HSUAN CHANG**, Associate Vice President Discovery and Early Development, AcuraStem

## SRITAMA BOSE

Head of Chemistry Research and Innovation, NATA

(RESERVED)

## ULRIKE RIEDER

Scientific Lead and Project Lead, Novartis

## NADIM AKHTAR

Senior Principal Scientist, AstraZeneca

## REETA DASWANI

Senior Scientist, Sixfold Bio

## SANDRA TREMMEL

Microbiology Engineer, Pharma Technical Product Quality - Analytical Sciences, F. Hoffmann-La Roche Ltd

## AURÉLIE LACROIX

Senior Scientist II, Sixfold Bio

## CHUN KONG MAK

Oligonucleotide Analytical Scientist, Synthon

## IJEOMA UCHEGBU

Professor of Pharmaceutical Nanoscience, University College London

## ZAHRA RATRAY

Senior Lecturer (Associate Professor) in Translational Pharmaceutics, University of Strathclyde

## SUSTAINABILITY IN BIOLOGICS & TIDES SPEAKERS

## FERNANDO ALBERICIO

Research Professor, University of Barcelona

(RESERVED)

## TIMOTHY WHITE

Senior Director, Eli Lilly

## LOUIS DIORAZIO

Senior Principal Scientist, New Modalities, AstraZeneca

## MICHAEL DELANEY

Principal Scientist, Novo Nordisk

## YI YANG

Principal Scientist, Ferring Pharmaceuticals

## DANIEL SEJER PEDERSEN

Chemical Development Specialist CMC API Development, Novo Nordisk

## ÁLVARO ENRÍQUEZ GARCÍA

Research Advisor, Eli Lilly

## AARON JOHN BALANA

Scientist III, Genentech

## WALTER CABRI

Full Professor of Organic Chemistry, University of Bologna

## ANNA MARIA PAPINI

Full Professor & Group Leader of PeptLab, University of Florence

## ALESSANDRA TOLOMELLI

Associate Professor, University of Bologna

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

Book Now

## Day One | Peptides, Oligonucleotide & Sustainability in Biologics & Tides Programmes

08:15

**Oxford Global's Welcome Address**

Welcome

08:25

**Opening Keynote Address & Fireside Chat With Keynote Speaker**

Benefits of Attending

### PEPTIDE DISCOVERY

### OLIGONUCLEOTIDE DISCOVERY

### PEPTIDES & OLIGO GREEN CHEMISTRY

09:25

**Track Keynote Address: Using Reinforcement Learning For Peptide Drug Discovery**

**Track Keynote Address: Cyclic Structured RNA Therapeutics**

**Track Keynote Address: Sustainable Peptide Synthesis Technologies**

Sponsors

IMMANUEL LERNER, Chief Executive Officer, **Pepticom**

SUDHIR AGRAWAL, Founder & President, & Affiliate Professor, **ARNAY Sciences & UMass Chan Medical School**

WALTER CABRI, Full Professor of Organic Chemistry, **University of Bologna**

Agenda at a Glance

09:50

**Peptide Design Updates**

**Oligo Delivery To The Eye And Brain**

**A Bioproduction Platform To Generate Functionalized Disulfide Constrained Peptides**

Proteins, Antibodies & ADCs Programme

JÁNOS KODRA, Principal Scientist, **Novo Nordisk**

MORTEN LINDOW, RNAHub Founder & Mission Lead, **F. Hoffmann-La Roche Ltd**

AARON JOHN BALANA, Scientist III, **Genentech**

Day 1 Day 2 Day 3

10:15

**Corporate / Diamond Solution Provider Presentation**

**Corporate / Diamond Solution Provider Presentation**

**Corporate / Diamond Solution Provider Presentation**

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

Day 1 Day 2 Day 3

### MORNING BREAK & REFRESHMENTS



1-2-1 Meetings x3



Poster Displays



Technology Showcase Presentations on the 'Visionary Voices' Stage



Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

10:40

**Roundtable 1: Improving Sustainable Chemistry Practices: Short Term Vs Long Term Solutions**

**Roundtable 2: Patent Strategies During Development Of Biologics**

**Roundtable 3: Nasal Delivery Of Biologics**

Moderator TBC

- What are the current opportunities to improve?
- Sustainable practices in pharma
- What are the technology leaps that could change the dynamic?

**Moderator:**  
LOUIS DIORAZIO, Senior Principal Scientist, New Modalities, **AstraZeneca**

**Moderator:**  
JEAN GE, Patent Attorney, **Wolf Greenfield**

- Delivery systems
- Modelling for delivery

**Moderator: (Reserved)** MARCO BECHERELLI, CMC Technical Leader Biologics, **Chiesi Pharmaceuticals**

Vaccines Programme

Day 1 Day 2 Day 3

11:40

**Sponsored Workshop**

**Sponsored Workshop**

**Sponsored Workshop**

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

Venue Information

Book Now

# Day One | Peptides, Oligonucleotide & Sustainability in Biologics & Tides Programmes

## PEPTIDE DISCOVERY

## OLIGONUCLEOTIDE DISCOVERY

## PEPTIDES & OLIGO GREEN CHEMISTRY

### LUNCH BREAK



1-2-1 Meetings x3



Poster Displays



### Thought-Leadership Panel Discussion: Bringing Novel Peptide Therapeutics Onto The Market

- Technological advancements driving production towards more cost effective and efficient methods
- Increasing the research and development investments by pharma
- Driving the demand of better technologies for peptide synthesis and drug delivery

**Moderator:** PAUL REID, Co-Founder & Chief Scientific Officer, Celtic Bio

**Panellists:**

IMMANUEL LERNER, Chief Executive Officer, Pepticom  
HELEN BRIGHT, Chief Scientific Officer, Centauri Therapeutics (Reserved)  
JOËL RICHARD, Chief Development Officer, Enterome

### Thought-Leadership Panel Discussion: Harnessing Oligonucleotide Therapeutic Development In 2025 And Beyond

- Growing use of synthetic oligo for therapeutic & diagnostic applications
- Developments in using novel technologies
  - » NGS CRISPR
- Growing focus on personalised medicine

**Moderator:** DAVID EVANS, Chief Scientific Officer, Sirnaomics

**Panellists:**

SUDHIR AGRAWAL, Founder & President, & Affiliate Professor, ARNAY Sciences & UMass Chan Medical School  
DAN SWERDLOW, Senior Director Discovery Medicine, GSK  
PRASUN CHAKRABORTY, Founder & Chief Executive Officer, Genevation

### Eco-Friendly Optimisation Of Automated Peptide Synthesis With Novel Binary Solvent Systems And Induction Heating

- Suitability of non-hazardous neat and mixed solvents
- Purification technologies
- Regulatory compliance

ANNA MARIA PAPINI, Full Professor & Group Leader of PeptLab, University of Florence

### Increasing Productivity In Oligo Production

LOUIS DIORAZIO, Senior Principal Scientist, New Modalities, AstraZeneca

### mRNA Display Based Discovery Of Cyclic Peptide Aptamers Based On Cryo-EM Characterisation Of Alpha-Conotoxin/Nachr Interactions

ANDREW JAMIESON, Professor of Chemical Biology, University of Glasgow

### Discovering The Best Target Indication Pairs For Oligonucleotides Therapeutics

DAN SWERDLOW, Senior Director Discovery Medicine, GSK

### Thought-Leadership Panel Discussion: Navigating The Paradigm Shift Towards Greener Approaches

- Regulatory updates
- Growing emphasis on sustainable practices
  - » From sustainable processes to sustainable supply chains
- Development and adoption of ecofriendly solutions

**Moderator:** WALTER CABRI, Full Professor of Organic Chemistry, University of Bologna

**Panellists:**

DANIEL SEJER PEDERSEN, Chemical Development Specialist CMC API Development, Novo Nordisk  
ANNA MARIA PAPINI, Full Professor & Group Leader of PeptLab, University of Florence  
LOUIS DIORAZIO, Senior Principal Scientist, New Modalities, AstraZeneca  
ALESSANDRA TOLOMELLI, Associate Professor, University of Bologna

### Structure-Based Design Of Anti-Viral Peptides

JUTTA EICHLER, Professor of Medicinal Chemistry, University of Erlangen-Nurnberg

### Analytical Strategies For Oligonucleotides

NADIM AKHTAR, Senior Principal Scientist, AstraZeneca



# Day One | Peptides, Oligonucleotide & Sustainability in Biologics & Tides Programmes

## PEPTIDE DISCOVERY

## OLIGONUCLEOTIDE DISCOVERY

## PEPTIDES & OLIGO GREEN CHEMISTRY

### AFTERNOON BREAK & REFRESHMENTS



1-2-1 Meetings x3



Poster Displays



Fireside Chats on the 'Visionary Voices' Stage



### Discovering Bioactive Peptides

IAN HAMLEY, Professor of Physical Chemistry, University of Reading

### Solving Delivery To Build The Future Of RNA Therapies

REETA DASWANI, Senior Scientist, Sixfold Bio

### High-Throughput Green Purification Methods

### Design And Optimisation Of Peptide-Based Antagonists Of The CGRP Receptor

CHRISTOPHER COXON, Senior Lecturer Medicinal Chemistry, The University of Edinburgh

### Novel Analytical Pipelines For Understanding Oligonucleotide-Loaded Lipid Nanoparticle Critical Quality Attributes

- This talk highlights the use of asymmetric flow field flow fractionation with inline detection for the high-resolution profiling nanoparticle critical quality attributes under formulation conditions and for testing interactions with biological systems
- We highlight some of the challenges faced in the sector and present case studies of some of our findings using this setup

ZAHRA RATTRAY, Senior Lecturer (Associate Professor) in Translational Pharmaceuticals, University of Strathclyde

### Achieving Sustainability In Oligo Synthesis

### ROUNDTABLE DISCUSSIONS & REGULATORY INSIGHT

#### Roundtable Discussion & Regulatory Insight: Regulatory Insights On Bringing A Peptide To Human Trials

- Regulations for venom peptides
- Navigating regulatory bodies
- Clinical trial design

**Moderator:** PAUL REID, Co-Founder & Chief Scientific Officer, Celtic Bio

#### Roundtable Discussion & Regulatory Insight: Analytical Control Strategies For Therapeutic Oligos

- Regulatory challenges
- Challenges with analysis of oligonucleotides

**Moderator:** NADIM AKHTAR, Senior Principal Scientist, AstraZeneca

#### Roundtable Discussion & Regulatory Insights: How Regulations Impact The Change To Sustainable Practices

Grab a drink & make your way to the Visionary Voices Stage for the end of day summaries

### CLOSE OF DAY ONE

Networking Drinks & Themed Bar Areas (Proteins, Antibodies & ADCs, Peptides, Oligonucleotides, Immunotherapy, Vaccines)

Canapés Reception

End of Day Summary x3

## Day Two | Peptides, Oligonucleotide & Sustainability in Biologics & Tides Programmes

08:30

*Come & join us for a refreshing start of the day*

09:00

### Keynote Address: Green Chemistry In Peptide Synthesis

FERNANDO ALBERICIO, Research Professor,  
**University of Barcelona**

#### PEPTIDE CHEMISTRY

##### Track Keynote Address: Drug Substance Manufacturing For Oncology Products

WILL NESBIT, Director of Process Chemistry & CMC,  
**Bicycle Therapeutics**

#### OLIGONUCLEOTIDE CHEMISTRY & CMC

##### Track Keynote Characterisation Of siRNA Product Related Impurities By HILIC

- The presentation will showcase the selection and synthesis of relevant siRNA product-related impurities.
- Development of a chromatographic method for separation of impurities through HILIC will be demonstrated.
- The ability of HILIC to complement other separation modes (AEX, IP-RP) will be discussed.

LUCAS BETHGE, Vice President & Group Leader of Oligonucleotide Chemistry,  
**Silence Therapeutics**

#### GREEN INNOVATIONS IN PEPTIDE & OLIGO MANUFACTURING

##### Track Keynote Address: Process Mass Intensity (PMI): A Holistic Analysis Of Current Peptide Manufacturing Processes Informs Sustainability In Peptide Synthesis

(Reserved) TIMOTHY WHITE, Senior Director,  
**Eli Lilly**

09:25

##### Development And Stability Of A Heat-Stable Peptide Formulation

- The leading cause of maternal mortality is post-partum haemorrhage PPH (bleeding) after childbirth. The majority (99%) of these deaths occur in low income countries. Oxytocin is effective in prevention and treatment of PPH but needs to be transported and stored in refrigerator, which can be hard to achieve in some parts of the world
- This presentation describes the formulation development of an oxytocin analogue, carbetocin, which resulted in a formulation stable for up to four years at 30°C, making it a good candidate for the battle against PPH

MATTIAS MALM, Senior Research Scientist,  
**Ferring Pharmaceuticals**

##### AI-Guided Oligo Process Optimisation Platform

GAL GUR, Vice President Business Development,  
**Anima Biotech**

##### Sustainable Peptide Manufacturing From A CMC Perspective

YI YANG, Principal Scientist,  
**Ferring Pharmaceuticals**

09:50

##### Platinum/Gold Solution Provider Presentation

*For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)*

##### Platinum/Gold Solution Provider Presentation

*For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)*

##### Platinum/Gold Solution Provider Presentation

*For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)*

10:15

### MORNING BREAK & REFRESHMENTS

10:40



1-2-1 Meetings x3



Poster Displays



Fireside Chats on the 'Visionary Voices' Stage



## Day Two | Peptides, Oligonucleotide & Sustainability in Biologics & Tides Programmes

### PEPTIDE CHEMISTRY

### OLIGONUCLEOTIDE CHEMISTRY & CMC

### GREEN INNOVATIONS IN PEPTIDE & OLIGO MANUFACTURING

#### Generative Models For Therapeutic Peptide Optimisation

LEONARDO DE MARIA, Principal Scientist, **AstraZeneca**

#### Novel Linkers For The Synthesis Of Oligonucleotide Conjugates

SRITAMA BOSE, Head of Chemistry Research & Innovation, **NATA**

#### Greener Approaches For Large Scale Peptide Manufacturing

• SPPS & tag-assisted PS  
DANIEL SEJER PEDERSEN, Chemical Development Specialist  
CMC API Development, **Novo Nordisk**

#### Gold And Above Solution Provider Presentation

For sponsorship opportunities  
please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

#### Gold And Above Solution Provider Presentation

For sponsorship opportunities  
please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

#### Gold And Above Solution Provider Presentation

For sponsorship opportunities  
please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

#### Engineering Microbes For The Discovery Of Cyclic Oligopeptide Rescuers Of Pathogenic Protein Misfolding And Aggregation

GEORGIOS SKRETAS, Director, Institute for Bio-innovation  
**Biomedical Sciences Research Center "Alexander Fleming"**

#### Analytical Strategies For Oligonucleotides

NADIM AKHTAR, Senior Principal Scientist, **AstraZeneca**

#### Solvent Sustainability In Medicinal Chemistry

• Solvent selection in discovery of pharmaceuticals  
• Where to focus on solvent replacement  
• Alternatives to unsustainable solvents  
• Green alternative synthetic protocols  
• Hazards of commonly used solvents  
• Automation and miniaturisation  
ÁLVARO ENRÍQUEZ GARCÍA, Research Advisor, **Eli Lilly**

### LUNCH BREAK



1-2-1 Meetings x3



Poster Displays



#### Solution Provider Presentation

Senior Representative.  
**PolyPeptide**



#### Solution Provider Presentation

Senior Representative.  
**A&M Stabtest**



#### Solution Provider Presentation

Senior Representative.  
**CPC Scientific**



Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme



Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes



Advances in Immunotherapy & Immunology Programme



Vaccines Programme



Innovation & Collaboration Programme



Venue Information

Book Now



## Day Two | Peptides, Oligonucleotide & Sustainability in Biologics & Tides Programmes

### PEPTIDE CHEMISTRY

### OLIGONUCLEOTIDE CHEMISTRY & CMC

### GREEN INNOVATIONS IN PEPTIDE & OLIGO MANUFACTURING

#### Peptides Imaging Agents For Clinical Applications

- Peptide Chemistry
- Biological Imaging
- Translation into Diagnostics

MARC VENDRELL, Professor,  
**University of Edinburgh**

#### Microbial Control Strategies For Oligo Drug Substance

SANDRA TREMMEL, Microbiology Engineer, Pharma Technical Product Quality- Analytical Sciences,  
**F. Hoffmann-La Roche**

#### Panel Discussion: How Can The Industry Navigate Changing Regulatory Landscapes Around Sustainability?

- Phasing out PFAS
- Implementing green processes in large pharma

**Moderator:** FERNANDO ALBERICIO, Research Professor,  
**University of Barcelona**

#### Panellists:

YI YANG, Principal Scientist, **Ferring Pharmaceuticals**  
DANIEL SEJER PEDERSEN, Chemical Development Specialist CMC API Development, **Novo Nordisk**

#### Roundtable Discussion 1: Metabolic Stability Of Therapeutic Cyclic Peptides

- Achieving sufficient stability for oral administration
- Mass spec fragmentation application
- Analytical tool in discovery and development

#### Co-Moderators:

MARIA FAWAZ, Associate Principal Scientist, **Merck & Co., Inc.** & KOMAL KEDIA, Associate Principal Scientist, **Merck & Co., Inc.**

#### Roundtable Discussion 2: Peptides Targeting The Central Nervous System

**Moderator:** CHRISTOPHER COXON, Senior Lecturer Medicinal Chemistry, **The University of Edinburgh**

#### Assessing Oligonucleotide Impurity

(Reserved) ULRIKE RIEDER, Scientific Lead and Project Lead,  
**Novartis**

#### Silver And Above Solution Provider Presentation

For sponsorship opportunities  
please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

#### Silver And Above Solution Provider Presentation

For sponsorship opportunities  
please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

#### Silver And Above Solution Provider Presentation

For sponsorship opportunities  
please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

### AFTERNOON BREAK & REFRESHMENTS



1-2-1 Meetings x3



Poster Displays



Fireside Chats on the  
'Visionary Voices' Stage



#### Silver And Above Solution Provider Presentation

For sponsorship opportunities  
please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

#### Silver And Above Solution Provider Presentation

For sponsorship opportunities  
please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

#### Silver And Above Solution Provider Presentation

For sponsorship opportunities  
please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

Book Now

## Day Two | Peptides, Oligonucleotide & Sustainability in Biologics & Tides Programmes

### PEPTIDE CHEMISTRY

### OLIGONUCLEOTIDE CHEMISTRY & CMC

### GREEN INNOVATIONS IN PEPTIDE & OLIGO MANUFACTURING

#### Panel Discussion: Exploring Chemical Modifications For The Optimisation Of Drug Candidates

- Formulation
- Chemical modification
- Relevant characteristics for a drug candidate

**Moderator:** IMMANUEL LERNER, Chief Executive Officer, Pepticom

**Panellists:**  
ANDREW JAMIESON, Professor of Chemical Biology, University of Glasgow  
LEONARDO DE MARIA, Principal Scientist, AstraZeneca

#### Roundtable Discussion 1: Peptides Vs Small Molecules And Other Chemical Spaces

- Advantages of using peptides vs small molecules
- Limitations of peptides

**Moderator:** MICHAL SHOSHAN, Group Leader, University of Zurich & Founder, metaLead

#### Roundtable Discussion 2: Expanding The Reach Of Chemical Peptides Through Machine Learning

**Moderator:** LEONARDO DE MARIA, Principal Scientist, AstraZeneca

#### Panel Discussion: Analytical Strategies For An Oligo IND

- Manufacturing & quality aspects of an oligo IND
- Characterisation & specifications
- Impurity testing
- Latest analytical technologies
- E2E microbial control strategies
- Application of modern & rapid microbial methods

**Moderator:** CHUN KONG MAK, Oligonucleotide Analytical Scientist, Synthron

**Panellists:**  
NADIM AKHTAR, Senior Principal Scientist, AstraZeneca  
SANDRA TREMMEL, Microbiology Engineer, Pharma Technical Product Quality - Analytical Sciences, F. Hoffmann-La Roche Ltd

#### Roundtable Discussion: The Relationship Between Chemistry And Oligo Delivery

- Chemistry of antisense helps provide drug-like properties and improves delivery to the appropriate cell compartment
- How does the nature of chemical modifications affect the choice of delivery modality
- Chemistry of conjugation-linker, site of conjugation and choice of conjugate

**Moderator:** SUDHIR AGRAWAL, Founder & President, & Affiliate Professor, ARNAY Sciences & UMass Chan Medical School

#### Challenges And Opportunities In The Manufacturing Of Oligonucleotides: Establishing An RNAi Production Strategy For Large Indications

MICHAEL DELANEY, Principal Scientist, Novo Nordisk

#### Roundtable Discussion 1: Promising Strategies For Extrahepatic Targeting

- Current concerns
- Nanoparticle-based RNA delivery
- Design strategies
- Future opportunities

**Moderator:** JIM WETERINGS, Vice President Research, Sirnaomics

#### Roundtable Discussion 2: Oligonucleotide Delivery Strategies & Best Practices

- Technology check-in: conjugates, particles & devices
- Connecting tissue, cargo, & delivery technology
- Scaling & CMC considerations – the earlier the better

**Moderator:** FELIX SCHUMACHER, Program Leader Targeted Therapeutics, F. Hoffmann-La Roche Ltd

#### Roundtable Discussion 3: Sustainability of CMC Manufacturing of Oligo Therapeutics

**Moderator:** MICHAEL DELANEY, Principal Scientist, Novo Nordisk

Grab a drink & make your way to the Visionary Voices Stage for the end of day summaries

### CLOSE OF DAY TWO

Poster Presentation Awards Ceremony

Networking Drinks

End of Day Summaries x3

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information






Book Now


# Day Three | Peptides, Oligonucleotide & Sustainability in Biologics & Tides Programmes

08:30 *Come & join us for a refreshing start of the day*

	PEPTIDE THERAPEUTICS & DEVELOPMENT	OLIGONUCLEOTIDE THERAPEUTIC DEVELOPMENT & OPTIMISATION	TOWARDS SUSTAINABLE SUPPLY CHAIN DEVELOPMENT & COMMERCIALISATION FOR BIOLOGICS
09:00	<p><b>Track Keynote Address: Knob Domain Peptides</b></p> <p>ALASTAIR LAWSON, Vice President and Immunology Fellow, <b>UCB</b></p>	<p><b>Track Keynote Address: siRNA To Treat Oncology Indications</b></p> <ul style="list-style-type: none"> <li>The presentation will showcase the selection and synthesis of relevant siRNA product-related impurities</li> <li>Development of a chromatographic method for separation of impurities through HILIC will be demonstrated</li> <li>The ability of HILIC to complement other separation modes (AEX, IP-RP) will be discussed</li> </ul> <p>DAVID EVANS, Chief Scientific Officer, <b>Sirnaomics</b></p>	<p><b>Track Keynote Address: Changes Towards A More Sustainable Supply Chain</b></p> <p>KUDA MUCHANDIBAYA, Lecturer for Supply Chain Management &amp; Logistics, <b>Rhine-Waal University of Applied Sciences</b></p>
09:25	<p><b>Gold And Above Solution Provider Presentation</b></p> <p><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i></p>	<p><b>Gold And Above Solution Provider Presentation</b></p> <p><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i></p>	<p><b>Gold And Above Solution Provider Presentation</b></p> <p><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i></p>
09:50	<p><b>High Affinity Bacteria-Derived Peptides: A Novel Approach To Generate Potent Anti-Tumor Immune Responses In Cancer Patients</b></p> <ul style="list-style-type: none"> <li>Identification and selection of strongly immunogenic bacterial peptides with sequence homology with tumor-associated antigens</li> <li>Peptide mimicry to induce a potent and sustained cross-reactive immune response through rapid memory T cell expansion</li> <li>Drug development challenges up to the Clinic</li> <li>Characterisation of the magnitude and polyfunctionality of the immune response</li> </ul> <p>JOËL RICHARD, Chief Development Officer, <b>Enterome</b></p>	<p><b>Utilizing the iNeuroTx Platform For Patient-Based Therapeutics</b></p> <p>WEN-HSUAN CHANG, Associate Vice President Discovery and Early Development, <b>AcuraStem</b></p>	<p><b>Ensuring Supply Chain Continuity</b></p>

## MORNING BREAK & REFRESHMENTS

10:15	 <p>1-2-1 Meetings x3</p> 	 <p>Poster Displays</p> 	 <p>Technology Showcases on the 'Visionary Voices' Stage</p> 	<p><b>Panel Discussion: Women In NextGen BioMed</b></p> <ul style="list-style-type: none"> <li>Breaking traditional barriers in STEM</li> <li>Women's newest contributions to biomedicine</li> <li>Challenges in breaking through the glass ceiling of the traditional biomedicine field</li> </ul> <p><b>Moderator:</b> AMITA VAIDYA, Principal Scientist, <b>Sanofi</b></p>
-------	--	--	---	---

11:15	<p><b>Solution Provider Presentation</b></p> <p>Senior Representative. <b>AmbioPharm Inc.</b></p> 	<p><b>Silver And Above Solution Provider Presentation</b></p> <p><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i></p>	<p><b>Silver And Above Solution Provider Presentation</b></p> <p><i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i></p>
-------	---	---	---

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

[Book Now](#)

# Day Three | Peptides, Oligonucleotide & Sustainability in Biologics & Tides Programmes

## PEPTIDE THERAPEUTICS & DEVELOPMENT

## OLIGONUCLEOTIDE THERAPEUTIC DEVELOPMENT & OPTIMISATION


## TOWARDS SUSTAINABLE SUPPLY CHAIN DEVELOPMENT & COMMERCIALISATION FOR BIOLOGICS

11:40  
**Developing Oral Peptide Therapeutics At The Speed Of Light**  
 PETE GOUGH, Chief Scientific Officer, **Nimble Therapeutics**

**Platform To Discover Oligonucleotide Medicines**  
 CHRISTOPHER HART, Chief Executive Officer, **Creyon Bio**

**Sustainable Storage Of Biologics**

12:05  
**Solution Provider Presentation**  
 Senior Representative.  
**Bachem**



**Solution Provider Presentation**  
 Senior Representative.  
**Biotage**



**Bronze And Above Solution Provider Presentation**



*For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)*

12:30  
**Nubytide: A Disease-Modifying Peptide That Offers Prevention And Treatment For Alzheimer's Disease**  
 NAZNEEN DEWJI, Founder & Chief Executive Officer, **Cenna Biosciences**

**Preclinical Expertise Of Taking An HBV ASO Into Phase 3**  
 STEVE HOOD, Senior Director, Oligonucleotide ADME Strategy, **GSK**

**Optimising Transportation Methods To Reduce Carbon Emissions**

## LUNCH BREAK

12:55 - 13:55  
 1-2-1 Meetings x3 

 Poster Displays 

13:55  
**Panel Discussion: Designing Peptides To Cross Biological Barriers**

- Organ-specific targeting
  - » Blood-brain barrier
- Oral delivery
- Cell-penetrating peptides
- The use of permeation enhancers and nanoparticles

**GalAhead™ muRNA: A Proprietary GalNAc-RNAi Therapeutic Platform For Simultaneous Downregulation Of Multiple Genes**

- Introduction to GalAhead™, Sirnaomics' GalNAc-RNAi therapeutic platform
- Validation of the GalAhead™ muRNA technology in vitro and in vivo
- Progress report on muRNA GalAhead-based program

JIM WETERINGS, Vice President Research, **Sirnaomics**

**Roundtable Discussion: The Science Behind A Sustainable Approach To Cosmetic Peptides**

- The role of cosmetic peptides
- Rational approach of new cosmeceutical ingredients
- Sustainable considerations

**Moderator:** ANNA MARIA PAPINI, Full Professor & Group Leader of PeptLab, **University of Florence**

14:20  
**Moderator:** JOËL RICHARD, Chief Development Officer, **Enterome**  
**Panellists:**  
 MARIE MCAVOY, Chief Scientific Officer, **NanoSyrinx**  
 MICHAL SHOSHAN, Group Leader, University of Zurich & Founder, **metaLead**  
 DAVID CRAIK, Director, **Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science**

**Diligent Design Of Antibody-Antisense Oligonucleotide Conjugate Architecture Enables Peripheral Drug Delivery To The Brain**

FELIX SCHUMACHER, Program Leader Targeted Therapeutics, **F. Hoffmann-La Roche Ltd**

**Raw Material Sourcing**

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immunology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

Book Now

## Day Three | Peptides, Oligonucleotide & Sustainability in Biologics & Tides Programmes

### PEPTIDE THERAPEUTICS & DEVELOPMENT

### OLIGONUCLEOTIDE THERAPEUTIC DEVELOPMENT & OPTIMISATION

### TOWARDS SUSTAINABLE SUPPLY CHAIN DEVELOPMENT & COMMERCIALISATION FOR BIOLOGICS

#### Solution Provider Presentation

Senior Representative.  
**Euro API**



#### Solution Provider Presentation

Senior Representative.  
**FyoniBio**



#### Bronze And Above Solution Provider Presentation

For sponsorship opportunities  
please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

#### Case Study From AstraZeneca: Peptide Therapeutics

MALIN LEMURELL, Executive Director & Head of Medicinal Chemistry CVRM Biopharmaceuticals R&D,  
**AstraZeneca**

#### The Future Of RNA Therapies

AURÉLIE LACROIX, Senior Scientist II,  
**Sixfold Bioscience**

#### The Future Of Sustainable Commercialisation For Biologics

### AFTERNOON BREAK & REFRESHMENTS

#### Peptides In Regenerative Medicine

STEPHEN MILLER, Principal Scientist,  
**Genentech**

#### Cyclotides As Ultra-stable Combinatorial Display Platforms For Peptide-Based Drug Discovery

- Cyclotides are ultra-stable macrocyclic peptides, and they are amenable to chemical synthesis
- Bioactive peptide epitopes can be grafted into them to stabilise the epitopes
- Designer cyclotides have been made to modulate a wide range of extracellular and intracellular targets
- Cyclotides can be recombinantly produced in a sustainable way

DAVID CRAIK, Director,  
**Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science**

#### Industry Workshop: Development Of Targeted Delivery Systems

##### Presentation 1: Targeted Delivery Of ASO Gapmers To Muscle For The Treatment Of Myotonic Dystrophy Type 1

SAUL MARTINEZ MONTERO, Senior Director, RNA Therapeutics,  
**Dyne Therapeutics**

##### Presentation 2: Delivery Of Nucleic Acids To The Brain

- Delivery of nucleic acids is difficult due to the blood brain barrier
- Delivery of nucleic acids via the nose to brain route targets nucleic acids to the cerebral cortex
- The nose to brain route may be used to deliver gene therapeutics for disease modifying applications

IJEOMA UCHEGBU, Professor of Pharmaceutical Nanoscience,  
**University College London**

#### Industry Workshop: Towards Sustainable Cell & Gene Therapy Manufacturing, Supply Chain, & Commercialisation

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

Book Now



## Day Three | Peptides, Oligonucleotide & Sustainability in Biologics & Tides Programmes

### PEPTIDE THERAPEUTICS & DEVELOPMENT

### OLIGONUCLEOTIDE THERAPEUTIC DEVELOPMENT & OPTIMISATION

### TOWARDS SUSTAINABLE SUPPLY CHAIN DEVELOPMENT & COMMERCIALISATION FOR BIOLOGICS

#### The Identification Of Cyclic Peptide Metabolic Soft Spots By Isotope-Labelled Reductive Dimethylation And Leveraging High-Resolution Ion Mobility-Mass Spectrometry

16:40

MARIA FAWAZ, Associate Principal Scientist, **Merck & Co., Inc.**

#### Short Peptides As Chelating Agents For Metal-Related Diseases

- Lead poisoning is an environmental worldwide health concern affecting millions of children and adults alike. Wilson's disease is a rare genetic condition causing the accumulation of copper in toxic amounts in various organs. In both cases, the only treatment modality is chelation therapy, which uses small primitive molecules as chelating agents.
- Short peptides are offered to address the drawbacks of chelation therapy and are expected to revolutionize the field in terms of efficacy and safety alike.
- In the talk, examples in both disease areas will be discussed.

MICHAL SHOSHAN, Group Leader, University of Zurich & Founder, **metaLead**

#### Industry Workshop Panel Discussion: The Next Chapter Of Oligonucleotide Delivery

- CNS & brain delivery
- Delivery to target tissues
- Extrahepatic delivery
- Delivery of antisense oligonucleotides

**Moderator:** STEVE HOOD, Senior Director, Oligonucleotide ADME Strategy, **GSK**

#### **Panellists:**

SAUL MARTINEZ MONTERO, Senior Director, RNA Therapeutics, **Dyne Therapeutics**

MORTEN LINDOW, RNAHub Founder & Mission Lead, **F. Hoffmann-La Roche Ltd**

SRITAMA BOSE, Head of Chemistry Research and Innovation, **NATA**

FAZEL SHABANPOOR, Co-Founder & Chief Scientific Officer and Associate Professor & Head of Pep & Oligo Therapeutics Lab, **Centron Bio & The Florey Institute**

#### (Cont.) Industry Workshop: Towards Sustainable Cell & Gene Therapy Manufacturing, Supply Chain, & Commercialisation

**End of Conference**

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

[Book Now](#)

# **Immunotherapy & Immuno-oncology** Programme Overviews


A carefully curated event packed with leading speakers, research and cutting-edge presentations on the latest advancements in the discovery & development of novel immunotherapies; advances in cellular, antibody and combination therapy development as well as personalised cancer therapy treatments.

**VPs, Directors & Senior Managers** from leading pharma & biotech companies and research institutions in the following fields and more:

- |                          |                            |                              |
|--------------------------|----------------------------|------------------------------|
| • Immunotherapy          | • Cellular Therapies       | • Gut Microbiota-Immune Axis |
| • Immuno-Oncology        | • Antibody Therapies       | • Clinical Development       |
| • Translational Medicine | • Pre-Clinical Development | • Process Development        |

**Formal and informal meeting opportunities** offer delegates the chance to discuss key solutions with leading service providers:

- |                                |                        |                           |
|--------------------------------|------------------------|---------------------------|
| • Translational Tools          | • Tumour Models        | • Screening Technologies  |
| • Checkpoint Marker Detection  | • Target Profiling     | • Druggability Assessment |
| • Immune Cell Characterisation | • Target Deconvolution | • Clinical Manufacturing  |


 Excellent event with delegates who are genuinely interested in services from the sponsors. As always an excellent event CLS are proud to sponsor.”  
 - BUSINESS DEVELOPMENT DIRECTOR, CONCEPT LIFE SCIENCES

# ADVANCES IN IMMUNOTHERAPY & IMMUNO-ONCOLOGY PROGRAMME

## Confirmed Speakers

KEY SPEAKERS



Day One | 09:50

Immunotherapy In AML  
**HESTER VAN ZEEBURG**, Project Manager Immunomonitoring, Mendus AB



Day One | 09:50

CAR T Cell Therapies For Solid Tumours: Moving Through The Generations  
**JOHN MAHER**, Chief Scientific Officer, Leucid



Day One | 09:50

**PHILIP BEER**, Chief Scientific Officer, Step Pharma



Day Two | 09:00

**DANIEL LAROCQUE**, Innovation Lead, Innovation and Emerging Science, Sanofi



Day Three | 09:00

**SHARAM LAVASANI**, Chief Executive Officer, ImmuneBiotech

### IMMUNOTHERAPY & IMMUNO-ONCOLOGY SPEAKERS

#### DANIEL LAROCQUE

Innovation Lead, Innovation and Emerging Science, Sanofi

#### HESTER VAN ZEEBURG

Project Manager Immunomonitoring, Mendus AB

#### TOMÁŠ HANKE

Professor in Vaccine Immunology, Oxford University

#### PHILIP BEER

Chief Scientific Officer, Step Pharma

#### JOHN MAHER

Chief Scientific Officer, Leucid

#### STINE FRIIS THORSEN,

Director Clinical Development, Evaxion

#### CHRISTIAN GARDE,

Director Bioinformatics, Evaxion

#### JILL WALKER

Immuno-Oncology Diagnostic Franchise Leader, Precision Medicine & Genomics, AstraZeneca

#### LIVJIA DEBAN

Chief Scientific Officer, Prokarium

#### SHARAM LAVASANI

Chief Executive Officer, ImmuneBiotech

#### RAYMOND TESI

President & Chief Executive Officer, InMune Bio

#### DAVID WRAITH

Emeritus Professor of Immunology, Institute of Immunology and Immunotherapy, University of Birmingham

#### KIRSTY CRAME

Vice President Clinical Strategy & Development, MediGene

#### LADA LEYENS

Senior Director EUCAN Regulatory TA, Head GI2, Takeda

#### TATYANA PONOMARYO

Principal Scientist, Plasticell

#### BALDUR SVEINBJØRNSSON

Chief Scientific Officer, Lytx Biopharma

#### BERNARD MAILLERE

Head of Laboratory, CEA

#### VALDIMIR KIRKIN

Director, Development Project Leader, Molecular Partners

#### YANN ABRAHAM

Associate Director AI for Single Cell, Janssen

(RESERVED)

#### CAROLINE LONEZ

Associate Director R&D, Celyad

#### ANNELISE VUIDEPOT

Senior Vice President, Chief Technology Officer, Research and UK Site Lead, Immunocore

#### MICHELLE WANTOCH

Senior Scientist, F-star Therapeutics

#### EMMA STANLEY

Director, Senior Program Lead & Head of Antibody Discovery, Mestag Therapeutic

#### MADS HALD ANDERSEN

Director, Professor, National Centre For Cancer Immune Therapy (CCIT-dk) Copenhagen University Hospital

#### JOERG RIPPMMANN,

Director, Global Cancer Immunology + Immune Modulation, Boehringer Ingelheim

(RESERVED)

#### BJORN ONFELT

Professor, KTH Royal Institute Of Technology

(RESERVED)

#### CECILE GEUIJEN

Chief Scientific Officer, Merus

(RESERVED)

#### BARBARA CIPRIANI

Vice President, Biology, Patheos Therapeutics

(RESERVED)

#### INMA RIOJA

Senior Vice President, Bicycle Therapeutics

(RESERVED)

#### DAVID CLOSE

Executive Clinical Director, AstraZeneca

(RESERVED)

#### CHRISTINE BOWMAN

Principal Investigator, Biology, Arcus Bioscience

(RESERVED)

#### ROMAIN LARA

Associate Director, Functional Genomics, AstraZeneca

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

Book Now

LinkedIn

@OGConferences

# Day One | Advances in Immunotherapy & Immuno-Oncology Programme

08:15 **Oxford Global's Welcome Address**

08:25 **Opening Keynote Address & Fireside Chat With Keynote Speaker**

IMMUNOTHERAPY STRATEGIES	DISCOVERY & DEVELOPMENT: CELL & GENE AND COMBINATION THERAPIES	BIOMARKERS, CTDNA, PRECISION MEDICINE & MULTI-OMICS IN IMMUNO-ONCOLOGY
<b>Track Keynote Address: To Be Confirmed</b>  ANNELOISE VUIDEPOT, Senior Vice President, Chief Technology Officer, Research and UK Site Lead, <b>Immunocore</b>	<b>Track Keynote Address: CAR T Cell Therapies For Solid Tumours: Moving Through The Generations</b>  JOHN MAHER, Chief Scientific Officer, <b>Leucid</b>	<b>Track Keynote Address</b>
<b>PART 1: TO TREAT CANCER</b>  <b>Immunotherapy In AML</b>  HESTER VAN ZEEBURG, Project Manager Immunomonitoring, <b>Mendus AB</b>	<b>To Be Confirmed</b>  KIRSTY CRAME, Vice President Clinical Strategy & Development, <b>MediGene</b>	<b>PART 1: BIOMARKERS &amp; OMICS</b>  <b>Industry Presentation</b>
<b>Corporate / Diamond Solution Provider Presentation</b>  For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a>	<b>Corporate / Diamond Solution Provider Presentation</b>  For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a>	<b>Corporate / Diamond Solution Provider Presentation</b>  For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a>

09:25

09:50

10:15

## MORNING BREAK & REFRESHMENTS

 <b>1-2-1 Meetings x3</b> 	 <b>Poster Displays</b> 	 <b>Technology Showcase Presentations on the 'Visionary Voices' Stage</b> 
--	--	--


## CROSS-PROGRAMME ROUNDTABLES

10:40

11:40

<b>Roundtable 1: Improving Sustainable Chemistry Practices: Short Term Vs Long Term Solutions</b> <ul style="list-style-type: none"> <li>•What are the current opportunities to improve?</li> <li>•Sustainable practices in pharma</li> <li>•What are the technology leaps that could change the dynamic?</li> </ul> <b>Moderator:</b> LOUIS DIORAZIO, Senior Principal Scientist, New Modalities, AstraZeneca	<b>Roundtable 2: Patent Strategies During Development Of Biologics</b>  <b>Moderator:</b> JEAN GE, Patent Attorney, Wolf Greenfield	<b>Roundtable 3: Nasal Delivery Of Biologics</b>  <ul style="list-style-type: none"> <li>•Delivery systems</li> <li>•Modelling for delivery</li> </ul> <b>Moderator: (Reserved)</b> MARCO BECHERELLI, CMC Technical Leader Biologics, Chiesi Pharmaceuticals	<b>Moderator TBC</b>
--	--	--	----------------------

11:40

<b>Platinum and Gold Solution Provider Presentation</b>  For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a>	<b>Platinum and Gold Solution Provider Presentation</b>  For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a>	<b>Solution Provider Presentation</b>  
--	--	--

### BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3






Venue Information

Book Now

LinkedIn

@OGConferences

Day One | Advances in Immunotherapy & Immuno-Oncology Programme

	IMMUNOTHERAPY STRATEGIES	DISCOVERY & DEVELOPMENT: CELL & GENE AND COMBINATION THERAPIES	BIOMARKERS, CTDNA, PRECISION MEDICINE & MULTI-OMICS IN IMMUNO-ONCOLOGY
12:05	Industry Presentation	To Be Confirmed	<b>Panel Discussion: Applications Of Liquid Biopsy Techniques In Precision Oncology</b> <ul style="list-style-type: none"> <li>Clinical applications in early cancer detection</li> <li>Monitoring tumour evolution and resistance</li> <li>Personalised treatment decisions</li> </ul>
12:30	Industry Presentation	To Be Confirmed	Industry Presentation
12:55	Platinum and Gold Solution Provider Presentation	Platinum and Gold Solution Provider Presentation	Solution Provider Presentation
	For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a>	For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a>	
<b>LUNCH BREAK</b>			
13:20 - 14:20	 1-2-1 Meetings x3 		 Poster Displays 
14:20 - 15:10	<b>Thought-Leadership Panel Discussion: Developing Novel Immunotherapy Modalities: Adapting Precision Immunology, Cancer Microbiome, And CAR-T Therapies For Patient Care</b> <ul style="list-style-type: none"> <li>Challenges in adapting different modalities to better patient care</li> <li>How to put patients at the forefront of drug development</li> </ul>		
15:10	<b>Leveraging Microbial Immunotherapies To Treat Cancer</b>  LIVJIA DEBAN, Chief Scientific Officer, <b>Prokarium</b>	<b>Panel Discussion: Cell Therapies To Treat Solid Tumours</b> <ul style="list-style-type: none"> <li>Long term effects of CAR T cell therapies for solid tumours</li> <li>What is the next step for CAR T development?</li> <li>Applications of solid tumour treatment techniques to treat auto immune diseases</li> </ul>	To Be Confirmed
15:35	<b>Single Cell AI Applications For Immunotherapy Treatments For Cancer</b>  YANN ABRAHAM, Associate Director AI for Single Cell, <b>Janssen</b>	To Be Confirmed	<b>PART 2: CTDNA</b>  <b>The Promise Of ctDNA: Challenges And How To Over Come Them</b>  JILL WALKER, Immuno-Oncology Diagnostic Franchise Leader, Precision Medicine & Genomics, <b>AstraZeneca</b>

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

Book Now

Day One | Advances in Immunotherapy & Immuno-Oncology Programme

IMMUNOTHERAPY STRATEGIES

DISCOVERY & DEVELOPMENT: CELL & GENE AND COMBINATION THERAPIES

BIOMARKERS, CTDNA, PRECISION MEDICINE & MULTI-OMICS IN IMMUNO-ONCOLOGY

AFTERNOON BREAK & REFRESHMENTS

16:00



1-2-1 Meetings x3



Poster Displays



Fireside Chats on the 'Visionary Voices' Stage



PART 2: TO TREAT AUTOIMMUNE DISEASES

Industry Presentation

To Be Confirmed

17:00

To Be Confirmed

(Reserved) CECILE GEUIJEN, Chief Scientific Officer, Merus

PHILIP BEER, Chief Scientific Officer, Step Pharma

17:25

To Be Confirmed

MADS HALD ANDERSEN, Director, Professor, National Centre For Cancer Immune Therapy (CCIT-dk) Copenhagen University Hospital

Industry Presentation

To Be Confirmed

ROMAIN LARA, Associate Director, Functional Genomics, AstraZeneca

17:50

Regulatory Roundtable Discussions

18:15

Grab a drink & make your way to the Visionary Voices Stage for the end of day summaries

CLOSE OF DAY ONE

18:20

Networking Drinks & Themed Bar Areas (Proteins, Antibodies & ADCs, Peptides, Oligonucleotides, Immunotherapy, Vaccines)

Canapés Reception

End of Day Summary x3

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3







Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

Book Now

## Day Two | Advances in Immunotherapy & Immuno-Oncology Programme

08:30	Come & join us for a refreshing start of the day		
09:00	<b>Co-Located Keynote Address: How The RNA Technologies Could Help To Prevent Infectious Diseases And Could Be Applied To Various Chronic Disease Immunotherapies</b> DANIEL LAROCQUE, Innovation Lead, Innovation and Emerging Science, <b>Sanofi</b>		
	NEW CLINICAL DEVELOPMENTS FOR IMMUNOTHERAPIES	PREDICTIVE MODELS & TOOLS FOR PRECLINICAL EVALUATION AND TRANSLATIONAL DEVELOPMENT	PERSONALISED CANCER THERAPIES
	<b>Track Keynote Address</b>	<b>Track Keynote Address: To Be Confirmed</b>	<b>Track Keynote Address</b>
09:25		(Reserved) ANDREAS REICHEL, Vice President, Head Of Preclinical Modeling & Simulation, <b>Bayer</b>	
09:50	<b>Conserved T-Cell Vaccines: Targeting HIV Where It Hurts</b> • We use pre-clinical and human data to inform iterative EM trials aiming to induce protective T cells and contribute to HIV cure. Our theorem is to attack functionally conserved protein regions with limited escape and high commonality among global variants: We target HIV's Achilles heel. The overall strategy, clinical programme and data from the first vaccine studies will be presented. TOMÁŠ HANKE, Professor in Vaccine Immunology, <b>Oxford University</b>	<b>Industry Presentation</b>	<b>Phase 2 Study Testing A Cancer Immunotherapy/ A Peptide-Based Cancer Vaccine In Melanoma</b>
		BARBARA CIPRIANI, Vice President, Biology, <b>Patheos Therapeutics</b>	STINE FRIIS THORSEN, Director Clinical Development, <b>Evaxion</b>
10:15	<b>Platinum/Gold Solution Provider Presentation</b>	<b>Platinum/Gold Solution Provider Presentation</b>	<b>Platinum/Gold Solution Provider Presentation</b>
	<i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i>	<i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i>	<i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i>
<b>MORNING BREAK &amp; REFRESHMENTS</b>			
10:40	 <b>1-2-1 Meetings x3</b> 	 <b>Poster Displays</b> 	 <b>Fireside Chats on the 'Visionary Voices' Stage</b> 
11:40	<b>To Be Confirmed</b>	<b>To Be Confirmed</b>	<b>To Be Confirmed</b>
	(Reserved) DAVID CLOSE, Executive Clinical Director, <b>AstraZeneca</b>	LADA LEYENS, Senior Director EUCAN Regulatory TA, Head GI2, <b>Takeda</b>	SHREENAL PATEL, Executive Vice President, Patient Supply Operations, <b>Achilles</b>
12:05	<b>Platinum/Gold Solution Provider Presentation</b>	<b>Platinum/Gold Solution Provider Presentation</b>	<b>Platinum/Gold Solution Provider Presentation</b>
	<i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i>	<i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i>	<i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i>

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3











Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

Book Now

## Day Two | Advances in Immunotherapy & Immuno-Oncology Programme

	NEW CLINICAL DEVELOPMENTS FOR IMMUNOTHERAPIES	PREDICTIVE MODELS & TOOLS FOR PRECLINICAL EVALUATION AND TRANSLATIONAL DEVELOPMENT	PERSONALISED CANCER THERAPIES
12:30	<b>Development Of Immunotherapies For Auto Immune Diseases</b> DAVID WRAITH, Emeritus Professor of Immunology, Institute of Immunology and Immunotherapy, <b>University of Birmingham</b>	<b>Recent Advances In Preclinical Immunogenicity Risk Assessment</b> BERNARD MAILLERE, Head of Laboratory, <b>CEA</b>	<b>To Be Confirmed</b> (Reserved) CAROLINE LONEZ, Associate Director R&D, <b>Celyad</b>
12:55 - 13:55	<b>LUNCH BREAK</b>		
	 1-2-1 Meetings x3		 Poster Displays 
13:55	<b>Silver And Above Solution Provider Presentation</b> For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a>	<b>Silver And Above Solution Provider Presentation</b> For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a>	<b>Silver And Above Solution Provider Presentation</b> For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a>
14:20	<b>Panel Discussion: AI/ML Antigen Selection For Immunotherapies</b> • AI-driven antigen discovery • Predicting neoantigens for personalized immunotherapies • Data-driven immunotherapy	<b>Panel Discussion: Immunogenicity In Immunotherapy Development</b> • Harnessing immunogenicity for cancer immunotherapies • Predictive tools for immunogenicity assessment	<b>Panel Discussion: Cancer Vaccines - Past, Present &amp; Future</b> • Cancer vaccine development updates • New approaches
14:45			
15:35	<b>AFTERNOON BREAK &amp; REFRESHMENTS</b>		
	 1-2-1 Meetings x3 	 Poster Displays 	 Fireside Chats on the 'Visionary Voices' Stage 
16:35	<b>Silver And Above Solution Provider Presentation</b> For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a>	<b>Silver And Above Solution Provider Presentation</b> For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a>	<b>Silver And Above Solution Provider Presentation</b> For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a>
17:00	<b>Targeting Glial As A Strategy To Treat Alzheimer's</b> RAYMOND TESI, President & Chief Executive Officer, <b>InMune Bio</b>	<b>To Be Confirmed</b> (Reserved) BJORN ONFELT, Professor, <b>KTH Royal Institute Of Technology</b>	<b>ERV (Endogenous Retrovirus) New Antigen Source For Cancer Immunotherapies And Evaxion's AI Model To Identify ERVs</b> CHRISTIAN GARDE, Director Bioinformatics, <b>Evaxion</b>
17:25	<b>To Be Confirmed</b> VALDIMIR KIRKIN, Director, Development Project Leader, <b>Molecular Partners</b>	<b>To Be Confirmed</b> JOERG RIPPMANN, Director, Global Cancer Immunology + Immune Modulation, <b>Boehringer Ingelheim</b>	<b>To Be Confirmed</b>

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

Book Now



**Day Two | Advances in Immunotherapy & Immuno-Oncology Programme**

	NEW CLINICAL DEVELOPMENTS FOR IMMUNOTHERAPIES	PREDICTIVE MODELS & TOOLS FOR PRECLINICAL EVALUATION AND TRANSLATIONAL DEVELOPMENT	PERSONALISED CANCER THERAPIES
17:50	Industry Presentation	Industry Presentation	Industry Presentation
18:15	Grab a drink & make your way to the Visionary Voices Stage for the end of day summaries		
<b>CLOSE OF DAY TWO</b>			
18:20	Poster Presentation Awards Ceremony Networking Drinks End of Day Summaries x3		

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3








Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

**Book Now**

**Day Three | Advances in Immunotherapy & Immuno-Oncology Programme**

08:30	<i>Come &amp; join us for a refreshing start of the day</i>		
	<b>MICROBIOME &amp; THE GUT-IMMUNE AXIS</b>	<b>DISCOVERY &amp; DEVELOPMENT: ANTIBODY THERAPIES</b>	<b>NOVEL TARGETS IN IMMUNO-ONCOLOGY: IDENTIFICATION, VALIDATION &amp; EXPLORATION</b>
	<b>Track Keynote Address: To Be Confirmed</b>	<b>Track Keynote Address</b>	<b>Track Keynote Address</b>
09:00	SHARAM LAVASANI, Chief Executive Officer, <b>ImmuneBiotech</b>		
	<b>Gold And Above Solution Provider Presentation</b>	<b>Gold And Above Solution Provider Presentation</b>	<b>Gold And Above Solution Provider Presentation</b>
09:25	<i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i>	<i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i>	<i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i>
	<b>Industry Presentation</b>	<b>To Be Confirmed</b>	<b>Industry Presentation</b>
09:50		CHRISTINE BOWMAN, Principal Investigator, Biology, <b>Arcus Bioscience</b>	
<b>MORNING BREAK &amp; REFRESHMENTS</b>			
10:15	 <b>1-2-1 Meetings x3</b> 	 <b>Poster Displays</b> 	 <b>Technology Showcases on the 'Visionary Voices' Stage</b> 
			<b>Panel Discussion: Women In NextGen BioMed</b> <ul style="list-style-type: none"> <li>• Breaking traditional barriers in STEM</li> <li>• Women's newest contributions to biomedicine</li> <li>• Challenges in breaking through the glass ceiling of the traditional biomedicine field</li> </ul> <b>Moderator:</b> AMITA VAIDYA, Principal Scientist, Sanofi
11:15	<b>Silver And Above Solution Provider Presentation</b>	<b>Silver And Above Solution Provider Presentation</b>	<b>Gold And Above Solution Provider Presentation</b>
	<i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i>	<i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i>	
	<b>Industry Presentation</b>	<b>Development Of Bispecific Antibodies For Immuno-Oncology</b>	<b>Industry Presentation</b>
11:40		EMMA STANLEY, Director, Senior Program Lead & Head of Antibody Discovery, <b>Mestag Therapeutic</b>	
12:05	<b>Bronze And Above Solution Provider Presentation</b>	<b>Bronze And Above Solution Provider Presentation</b>	<b>Bronze And Above Solution Provider Presentation</b>
	<i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i>	<i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i>	<i>For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.com">sponsorship@oxfordglobal.com</a></i>

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

**Book Now**

# Day Three | Advances in Immunotherapy & Immuno-Oncology Programme

## MICROBIOME & THE GUT-IMMUNE AXIS

## DISCOVERY & DEVELOPMENT: ANTIBODY THERAPIES

## NOVEL TARGETS IN IMMUNO-ONCOLOGY: IDENTIFICATION, VALIDATION & EXPLORATION

Industry Presentation

Industry Presentation

Track Keynote Address

### LUNCH BREAK



1-2-1 Meetings x3



Poster Displays



### Panel Discussion: Next-Generation Immunotherapies: Novel Approaches And Platforms

- Cutting-edge immunotherapies: bispecific antibodies, CAR-T cells, CAR-NK cells, and TCR-engineered therapies
- Cell-based immunotherapies and their applications beyond cancer

Industry Presentation

Industry Presentation

Industry Presentation

Industry Presentation

### Bronze And Above Solution Provider Presentation

For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

### Bronze And Above Solution Provider Presentation

For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

### Bronze And Above Solution Provider Presentation

For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

Industry Presentation

Industry Workshop

Industry Presentation

### AFTERNOON BREAK & REFRESHMENTS

Industry Presentation

Industry Presentation

Industry Presentation

Industry Presentation

Industry Presentation

Industry Presentation

Industry Presentation

Industry Presentation

Industry Presentation

Industry Presentation

Industry Presentation

Industry Presentation

End of Conference

## BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme


Day 1 Day 2 Day 3

Venue Information

Book Now

LinkedIn

@OGConferences



# Vaccines Programme Overviews

Delve into the latest in immunotherapy and vaccine discovery and development: from advanced nucleotide based platforms for infectious diseases, to antigen development, to immunotherapy strategies for cancer and autoimmune disease, through to novel delivery systems & adjuvant production.

**VPs, Directors & Senior Managers** from leading pharma & biotech companies and research institutions in the following fields and more:

- |                       |                      |                  |
|-----------------------|----------------------|------------------|
| • Vaccine Research    | • Infectious Disease | • Viral Vaccines |
| • Vaccine Development | • Vaccine Analytics  | • mRNA Vaccines  |
| • Virology            | • Vaccine CMC        | • Antigen Design |

**Formal and informal meeting opportunities** offer delegates the chance to discuss key solutions with leading service providers:

- |                                 |                          |                        |
|---------------------------------|--------------------------|------------------------|
| • Animal Models                 | • Adjuvant Selection     | • Stability Testing    |
| • Antigen Production            | • Analytical Development | • Safety Testing       |
| • Viral Genome Characterisation | • Vaccine Optimisation   | • Vaccine Construction |

“Biologics 2024 was one of the best conferences I have attended so far in my career. Good talks, scientists wanting to talk to service/reagent providers, good food and networking events.”

- TERRITORIAL SALE MANAGER UK, ACRO BIOSYSTEMS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

Book Now




VACCINES PROGRAMME  
**Confirmed Speakers**

SPEAKERS



Day One | 09:25

The Pivotal Role Of RNA Vaccine Technology In CEPI's 100 Day Mission  
**MARTINA OCHS**, Project Leader - mRNA Program, CEPI



Day Two | 09:50

Development Of A Cell-Based Potency Assay To Support Scancell's DNA Vaccine Platforms  
**ELISA MARELLI**, Research Scientist, Scancell



Day Two | 11:40

Smallpox Vaccine: Lessons From The Mpxv Outbreak  
**ASHLEY OTTER**, Group Leader, Emerging Pathogen Serology, UK Health Security Agency



Day Three | 09:00

Taking The Right Steps In Preclinical Development To Achieve Clinical Success  
**BRIAN SCHANEN**, Global Head of Biomarkers, Sanofi



Day Three | 09:50

Lessons Learned From Successful Delivery Of Covid Vaccinations In The UK  
**MARIA KOUFALI**, Director, Research and Innovation, UK Vaccine Innovation Pathway

VACCINES SPEAKERS

**MARIA KOUFALI**  
Director, Research and Innovation, UK Vaccine Innovation Pathway

**BRIAN SCHANEN**  
Global Head of Biomarkers, Sanofi

**CALLUM SCOTT**  
Head of Development, Scancell

**MARTINA OCHS**  
Project Leader - mRNA Program, CEPI

**ASHLEY OTTER**  
Group Leader, Emerging Pathogen Serology, UK Health Security Agency

**ELISA MARELLI**  
Research Scientist, Scancell

*(Reserved)*  
**IRINA MELN**  
Head of Innovation, European Vaccine Initiative

CHECK BACK SOON FOR MORE SPEAKERS

BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

Book Now

LinkedIn

@OGConferences

# Day One | Vaccines Programme

## NUCLEOTIDES, BIOLOGICS & OTHER VACCINE PLATFORMS FOR INFECTIOUS DISEASES & ANTIGEN DEVELOPMENT

08:15

**Oxford Global's Welcome Address**

08:25

**Opening Keynote Address & Fireside Chat With Keynote Speaker**

09:25

**Track Keynote Address: The Pivotal Role Of RNA Vaccine Technology In CEPI's 100 Day Mission**

- CEPI's 100 Day Mission
- The role of platforms to support this mission
- CEPI's investment in RNA vaccine technology

MARTINA OCHS, Project Leader - mRNA Program, **CEPI**

09:50

**Industry Presentation**

10:15

**Corporate / Diamond Solution Provider Presentation**

For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

09:50

**Industry Presentation**

### MORNING BREAK & REFRESHMENTS



1-2-1 Meetings x3



Poster Displays



Technology Showcase Presentations on the 'Visionary Voices' Stage



### CROSS-PROGRAMME ROUNDTABLES

10:40

11:40

**Roundtable 1: Improving Sustainable Chemistry Practices: Short Term Vs Long Term Solutions**

- What are the current opportunities to improve?
- Sustainable practices in pharma
- What are the technology leaps that could change the dynamic?

**Moderator:**  
LOUIS DIORAZIO, Senior Principal Scientist, New Modalities, AstraZeneca

**Roundtable 2: Patent Strategies During Development Of Biologics**

**Moderator:**  
JEAN GE, Patent Attorney, Wolf Greenfield

**Roundtable 3: Nasal Delivery Of Biologics**

- Delivery systems
- Modelling for delivery

**Moderator: (Reserved)** MARCO BECHERELLI, CMC Technical Leader Biologics, Chiesi Pharmaceuticals

Moderator TBC

11:40

**Platinum and Gold Solution Provider Presentation**

For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

Book Now

# Day One | Vaccines Programme

## NUCLEOTIDES, BIOLOGICS & OTHER VACCINE PLATFORMS FOR INFECTIOUS DISEASES & ANTIGEN DEVELOPMENT

### Panel Discussion: Benchmarking Current Vaccine Platforms

- mRNA, DNA vaccine & recombinant protein-based platforms
- Peptides & virus-like particles-based platforms
- Stability, efficacy of platforms
- Analytical test methods – potency
- Scalability & manufacturability
- Cold chain storage

**Moderator:** CALLUM SCOTT, Head of Development, Scancell

### Platinum and Gold Solution Provider Presentation

For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

### LUNCH BREAK



1-2-1 Meetings x3



Poster Displays



### Thought-Leadership Panel Discussion: Building The Next Generation Of Vaccines For Infectious Diseases

- Adapting vaccines for emerging and re-emerging diseases
- Universal vaccines; Long-term immunity & booster doses

### Industry Presentation

### Industry Presentation

### AFTERNOON BREAK & REFRESHMENTS



1-2-1 Meetings x3



Poster Displays



Fireside Chats on the  
'Visionary Voices' Stage



### Industry Presentation

### Industry Presentation

### Regulatory Roundtable Discussions

## BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

Book Now

LinkedIn

@OGConferences

## Day One | Vaccines Programme

### NUCLEOTIDES, BIOLOGICS & OTHER VACCINE PLATFORMS FOR INFECTIOUS DISEASES & ANTIGEN DEVELOPMENT

18:15 *Grab a drink & make your way to the Visionary Voices Stage for the end of day summaries*

#### CLOSE OF DAY ONE

18:20 **Networking Drinks & Themed Bar Areas (Proteins, Antibodies & ADCs, Peptides, Oligonucleotides, Immunotherapy, Vaccines)**  
**Canapés Reception**  
**End of Day Summary x3**

## Day Two | Vaccines Programme

### VACCINE ANALYTICAL TESTING & STABILITY

08:30 *Come & join us for a refreshing start of the day*

#### Co-Located Keynote Address: How The RNA Technologies Could Help To Prevent Infectious Diseases And Could Be Applied To Various Chronic Disease Immunotherapies

09:00 DANIEL LAROCQUE, Innovation Lead, Innovation and Emerging Science, **Sanofi**

#### Track Keynote Address

#### Development Of A Cell-Based Potency Assay To Support Scancell's DNA Vaccine Platforms

09:50 ELISA MARELLI, Research Scientist, **Scancell**

#### Platinum and Gold Solution Provider Presentation

10:15 *For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)*

#### MORNING BREAK & REFRESHMENTS



1-2-1 Meetings x3



Poster Displays



Fireside Chats on the 'Visionary Voices' Stage



#### Smallpox Vaccine: Lessons From The Mpox Outbreak

11:40 ASHLEY OTTER, Group Leader, Emerging Pathogen Serology, **UK Health Security Agency**



## Day Two | Vaccines Programme

### Gold And Above Solution Provider Presentation

12:05

For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

### Understanding The Heterogeneity Of mRNA / LNP Formulations

12:30

AMITA VAIDYA, Principal Scientist,  
**Sanofi**

### LUNCH BREAK

12:55

13:55



1-2-1 Meetings x3



Poster Displays



### Silver And Above Solution Provider Presentation

13:55

Senior Representative,  
**NOF Corporation**

 **NOF CORPORATION**

### Panel Discussion: Unveiling The Next Generation Of mRNA Analytical Development

14:20

14:45

- Advances in analytical tools and novel approaches towards analysing and quantifying mRNA medicines
- Highlighting the benefits and prospects of novel analytical and biological technologies compared to conventional approaches
- Drawing cross-learnings from different systems to overcome overlapping challenges and improve mRNA analytics
- Learning from diverse platforms to address shared hurdles and enhance analytical strategies

### Silver And Above Solution Provider Presentation

15:15

For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

### AFTERNOON BREAK & REFRESHMENTS

15:35



1-2-1 Meetings x3



Poster Displays



Fireside Chats on the  
'Visionary Voices' Stage



### Silver And Above Solution Provider Presentation

16:35

For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

### Industry Presentation

17:00

## BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

Book Now

LinkedIn

@OGConferences

## Day Two | Vaccines Programme

### Industry Presentation

17:25

### Industry Presentation

17:50

*Grab a drink & make your way to the Visionary Voices Stage for the end of day summaries*

### CLOSE OF DAY TWO

Poster Presentation Awards Ceremony

Networking Drinks

End of Day Summaries x3

18:20

## Day Three | Vaccines Programme

### PRECLINICAL INNOVATION & CLINICAL DEVELOPMENT FOR MRNA VACCINES

*Come & join us for a refreshing start of the day*

08:30

### Track Keynote Address: Taking The Right Steps In Preclinical Development To Achieve Clinical Success

BRIAN SCHANEN, Global Head of Biomarkers, **Sanofi**

09:00

### Platinum and Gold Solution Provider Presentation

*For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)*

09:25

### Lessons Learned From Successful Delivery Of Covid Vaccinations In The UK

MARIA KOUFALI, Director, Research and Innovation, **UK Vaccine Innovation Pathway**

09:50

### MORNING BREAK & REFRESHMENTS



1-2-1 Meetings x3



Poster Displays



Technology Showcases on the 'Visionary Voices' Stage



### Panel Discussion: Women In NextGen BioMed

- Breaking traditional barriers in STEM
- Women's newest contributions to biomedicine
- Challenges in breaking through the glass ceiling of the traditional biomedicine field

**Moderator:** AMITA VAIDYA, Principal Scientist, Sanofi

10:15

## Day Three | Vaccines Programme

### Silver And Above Solution Provider Presentation

11:15

For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

### Industry Presentation

11:40

### Silver And Above Solution Provider Presentation

12:05

For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

### Industry Presentation

12:30

### LUNCH BREAK



1-2-1 Meetings x3



Poster Displays



### Industry Presentation

11:40

### Silver And Above Solution Provider Presentation

12:55

For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

### Industry Presentation

13:55

### Industry Presentation

14:20

### Bronze And Above Solution Provider Presentation

14:45

For sponsorship opportunities please contact [sponsorship@oxfordglobal.com](mailto:sponsorship@oxfordglobal.com)

### Industry Presentation

15:10

## BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1

Day 2

Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1

Day 2

Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1

Day 2

Day 3

Vaccines Programme

Day 1

Day 2

Day 3

Innovation & Collaboration Programme

Day 1

Day 2

Day 3

Venue Information

Book Now

LinkedIn

@OGConferences

## Day Three | Vaccines Programme

### AFTERNOON BREAK & REFRESHMENTS

#### Panel Discussion: Lessons Learnt From Preclinical To Clinical Translation

- Translation of preclinical findings into clinical efficacy and safety data for mRNA vaccines
- Key challenges & successes

#### Panellists:

BRIAN SCHANEN, Global Head of Biomarkers, Sanofi

#### Industry Presentation

End of Conference

## BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

Book Now

LinkedIn

@OGConferences

# Inspiring Tomorrow's Breakthroughs: Unleashing Innovation & Collaboration in NextGen Biomed

Participate engaging presentations in our innovation and collaboration track across all three days, inspiring growth and creating space for collaboration opportunities for all who attend. The core attendee mix includes early-stage and emerging biotech or (academic) spinoff companies developing their own platforms or technologies.

## Featuring Attendees from Biotech and/or (Academic) Spinoff Companies Interested In:

- Seeking collaboration partners with pharma and solution providers
- Discovering new investment opportunities with pharma
- Learning about the latest industry trends & challenges
- Keeping updated with new innovations and technology solutions
- Showcasing their company profile to a targeted and engaged audience

## Format:

The Innovation & Collaboration track will comprise of over 20, 10-minute presentations from therapeutic development biotechs across 3-days, panel discussions and Q&As, encouraging networking, facilitating collaborations & showcasing emerging innovations in biologics, peptides oligonucleotides through to the development of novel immunotherapies & vaccines for infectious diseases.

Welcome

Benefits of  
Attending

Sponsors

Agenda at a  
Glance

Proteins,  
Antibodies &  
ADCs Programme

Day 1 Day 2 Day 3

Peptides,  
Oligonucleotide  
& Sustainability  
in Tides &  
Biologics  
Programmes

Day 1 Day 2 Day 3

Advances in  
Immunotherapy  
& Immuno-  
Oncology  
Programme

Day 1 Day 2 Day 3

Vaccines  
Programme

Day 1 Day 2 Day 3

Innovation &  
Collaboration  
Programme

Day 1 Day 2 Day 3

Venue  
Information

Book Now



# Confirmed Speakers

KEY SPEAKERS



Day Two | 09:25

Alphamers - A Novel Immunotherapy Platform For Treating Infectious Disease And Oncology

**HELEN BRIGHT**, Chief Scientific Officer, Centauri Therapeutics



Day Two | 09:25

Application of Natural Peptides in Therapies

**PAUL REID**, Co-Founder & Chief Scientific Officer, Celtic Bio



Day Two | 13:55

Immunotherapy Strategies To Treat Cancer

**BALDUR SVEINBJÖRNSSON**, Chief Scientific Officer, Lytix Biopharma



Day Two | 09:50

Modulating The Immune System To Treat Solid Tumours

**DAVID PEJOSKI**, Co-Founder & Chief Executive Officer, Adoram Therapeutics



Day Three | 14:20

Delivering Intercellular Therapeutic Proteins Using A Novel Technology

**MARIE MCAVOY**, Chief Scientific Officer, NanoSyrinx

## 2025 INNOVATION AND COLLABORATION SPEAKERS

### PRASUN CHAKRABORTY

Founder & Chief Executive Officer, Genevation

### ILARIA POLEDRI

Co-Founder & Chief Executive Officer, ExCulture Biotech

### HANS MELO

Co-Founder & Chief Executive Officer, Menten AI

### PAUL REID

Co-Founder & Chief Scientific Officer, Celtic Bio

### STEVEN SCHMITT

Co-Founder & Chief Executive Officer, Myria Biosciences

### FAZEL SHABANPOOR

Co-Founder & Chief Scientific Officer & Associate Professor & Head of Pep & Oligo Therapeutics Lab, Centron Bio & The Florey Institute

### DAN HARDY

Chief Executive Officer, Microsol Science

### HELEN BRIGHT

Chief Scientific Officer, Centauri Therapeutics

### SIMON PLYTE

Chief Scientific Officer, Biomunex Pharmaceuticals

### MARIE MCAVOY

Chief Scientific Officer, NanoSyrinx

### ANDREW SLEE

Chief Operating Officer, Protagenic Therapeutics

### LUIS GÓMEZ-MORALES

Scientific Project Manager, Pepkon

### PAWEL STOCKI

Vice President, R&D, Ossianix

### ALESSANDRO GORI

Group Leader, Italian National Research Council

### DAVID PEJOSKI

Co-Founder & Chief Executive Officer, Adoram Therapeutics

### BALDUR SVEINBJÖRNSSON

Chief Scientific Officer, Lytix Biopharma

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

Book Now

## Day One | Innovation & Collaboration Programme

### Presentation 1: Mixed Culture Fermentation For Biopharmaceutical Production

ILARIA POLEDRI, Co-Founder & Chief Executive Officer,  
**ExCulture**

### Presentation 2: Peptide Discovery Case Study

STEVEN SCHMITT, Chief Executive Officer & Co-Founder,  
**Myria Biosciences**

### Presentation 1: Utilising TCAP For Stress Related Disorders

ANDREW SLEE, Chief Operating Officer,  
**Protagenic Therapeutics**

### Presentation 2: Designing Peptides With AI/ML

HANS MELO, Co-Founder and Chief Executive Officer,  
**Menten AI**

Attendees are welcome to attend co-located sessions

### MORNING BREAK & REFRESHMENTS



1-2-1 Meetings x3



Poster Displays



Technology Showcase Presentations  
on the 'Visionary Voices' Stage



### CROSS-PROGRAMME ROUNDTABLES

#### Roundtable 1: Improving Sustainable Chemistry Practices: Short Term Vs Long Term Solutions

- What are the current opportunities to improve?
- Sustainable practices in pharma
- What are the technology leaps that could change the dynamic?

**Moderator:**  
LOUIS DIORAZIO, Senior Principal Scientist,  
New Modalities, AstraZeneca

#### Roundtable 2: Patent Strategies During Development Of Biologics

**Moderator:**  
JEAN GE, Patent Attorney,  
Wolf Greenfield

#### Roundtable 3: Nasal Delivery Of Biologics

- Delivery systems
- Modelling for delivery

**Moderator:** (Reserved) MARCO BECHERELLI,  
CMC Technical Leader Biologics, Chiesi  
Pharmaceuticals

Moderator TBC

Attendees are welcome to attend co-located sessions

### LUNCH BREAK



1-2-1 Meetings x3



Poster Displays



Welcome

Benefits of  
Attending

Sponsors

Agenda at a  
Glance

Proteins,  
Antibodies &  
ADCs Programme

Day 1 Day 2 Day 3

Peptides,  
Oligonucleotide  
& Sustainability  
in Tides &  
Biologics  
Programmes

Day 1 Day 2 Day 3

Advances in  
Immunotherapy  
& Immuno-  
Oncology  
Programme

Day 1 Day 2 Day 3

Vaccines  
Programme

Day 1 Day 2 Day 3

Innovation &  
Collaboration  
Programme

Day 1 Day 2 Day 3

Venue  
Information

Book Now

## Day One | Innovation & Collaboration Programme

### Presentation 1: Delivering Intercellular Therapeutic Proteins Using A Novel Technology

MARIE MCAVOY, Chief Scientific Officer,  
**NanoSyrinx**

### Presentation 2: Developing Personalised Cancer mRNA Vaccines

PRASUN CHAKRABORTY, Founder & Chief Executive Officer,  
**Genevation**

### Panel Discussion: Facilitating Collaborations & Partnerships In 2025

- Emerging technologies
- Cross-sector partnership

**Moderator:** STEVEN SCHMITT, Chief Executive Officer & Co-Founder, Myria Biosciences

#### Panellists:

HANS MELO, Co-Founder and Chief Executive Officer, Menten AI

HELEN BRIGHT, Chief Scientific Officer, Centauri

PAWEL STOCKI, Vice President, R&D, Ossianix

## AFTERNOON BREAK & REFRESHMENTS



1-2-1 Meetings x3



Poster Displays



Fireside Chats on the  
'Visionary Voices' Stage



### Presentation 1: Membrane-Sensing Peptides For Multi-Scale Extracellular Vesicles Isolation

ALESSANDRO GORI, Group Leader,  
**Italian National Research Council**

### Presentation 2: To Be Confirmed

LUIS GÓMEZ-MORALES, Scientific Project Manager,  
**Pepkon**

### Presentation 1: Novel Transferrin Receptor (TfR1) Brain Shuttles For Transforming The Treatment Of CNS Diseases

PAWEL STOCKI, Vice President, R&D,  
**Ossianix**

### Presentation 2: Finding The Patient Friendly Delivery Route For Your Peptides

SANDRIEN JANSSENS, R&D Director, CMC,  
**Mosanna Therapeutics**

## Q&A SESSION WITH THE SPEAKERS

*Grab a drink & make your way to the Visionary Voices Stage for the end of day summaries*

## CLOSE OF DAY ONE

Networking Drinks & Themed Bar Areas (Proteins, Antibodies & ADCs, Peptides, Oligonucleotides, Immunotherapy, Vaccines)

Canapés Reception & End of Day Summary x3

## BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1

Day 2

Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1

Day 2

Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1

Day 2

Day 3

Vaccines Programme

Day 1

Day 2

Day 3

Innovation & Collaboration Programme

Day 1

Day 2

Day 3

Venue Information

Book Now

LinkedIn

@OGConferences



## Day Two | Innovation & Collaboration Programme

08:30

*Come & join us for a refreshing start of the day*

### **Presentation 1: Alphas - A Novel Immunotherapy Platform For Treating Infectious Disease And Oncology**

- Alphas engage naturally occurring polyclonal anti-glycan antibodies that are present at high titre in everyone
- Alphas consist of a targeting domain that binds to the cell surface and a linker which presents a glycan domain which in turn recruits anti-glycan antibodies onto the cell and activates rapid immune clearance

HELEN BRIGHT, Chief Scientific Officer,  
**Centauri Therapeutics**

09:25

### **Presentation 2: Application of Natural Peptides in Therapies**

PAUL REID, Co-Founder & Chief Scientific Officer,  
**Celtic Bio**

### **Presentation 1: Modulating The Immune System To Treat Solid Tumours**

DAVID PEJOSKI, Co-Founder & Chief Executive Officer,  
**Adoram Therapeutics**

09:50

### **Presentation 2: The Development Of Peptide-Oligonucleotide Hybrids As Antisense Therapy In The Treatment Of Neurodegenerative Diseases**

FAZEL SHABANPOOR, Co-Founder & Chief Scientific Officer and Associate Professor & Head of Pep & Oligo Therapeutics Lab,  
**Centron Bio & The Florey Institute**

10:15

*Attendees are welcome to attend co-located sessions*

## MORNING BREAK & REFRESHMENTS

10:40



1-2-1 Meetings x3



Poster Displays



Fireside Chats on the  
'Visionary Voices' Stage



11:40

### **Presentation 1: New Biologic Modalities**

SIMON PLYTE, Chief Scientific Officer,  
**Biomunex Pharmaceuticals**

### **Presentation 2: Biologics Discovery**

*(Reserved)* RODRIGO ABREU, Principal Scientist,  
**LifeArc**

12:05

*Attendees are welcome to attend co-located sessions*

12:30

**Q&A SESSION WITH THE MORNING SPEAKERS OF THE TRACK**

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1

Day 2

Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1

Day 2

Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1

Day 2

Day 3

Vaccines Programme

Day 1

Day 2

Day 3

Innovation & Collaboration Programme

Day 1

Day 2

Day 3

Venue Information

[Book Now](#)

## Day Two | Innovation & Collaboration Programme

### LUNCH BREAK



1-2-1 Meetings x3



Poster Displays



### Presentation 1: Immunotherapy Strategies To Treat Cancer

BALDUR SVEINBJÖRNSSON, Chief Scientific Officer,  
**Lytix Biopharma**

### Presentation 2

*Attendees are welcome to attend co-located sessions*

### AFTERNOON BREAK & REFRESHMENTS



1-2-1 Meetings x3



Poster Displays



Fireside Chats on the  
'Visionary Voices' Stage



*Attendees are welcome to attend co-located sessions*

### Panel Discussion: Utilising AI/ML For Drug Discovery

- How can the implementation of AI/ML improve processes for drug discovery?

### Q&A SESSION WITH THE AFTERNOON SPEAKERS OF THE TRACK

*Grab a drink & make your way to the Visionary Voices Stage for the end of day summaries*

### CLOSE OF DAY TWO

Poster Presentation Awards Ceremony

Networking Drinks

End of Day Summaries x3

## BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

Book Now

LinkedIn

@OGConferences

## Day Three | Innovation & Collaboration Programme

08:30

*Come & join us for a refreshing start of the day*

Welcome

09:00

### PRESENTATIONS OF THE WINNERS OF THE 'YSA POSTER PRESENTATIONS'

Benefits of Attending

09:25

*Attendees are welcome to attend co-located sessions*

Sponsors

09:50

#### Presentation 1: Inhaled Delivery Of Biologics

DAN HARDY, Chief Executive Officer,  
**Microsol Science**

Agenda at a Glance

#### Presentation 2

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

### MORNING BREAK & REFRESHMENTS

10:15



1-2-1 Meetings x3



Poster Displays



Technology Showcases on the 'Visionary Voices' Stage



#### Panel Discussion: Women In NextGen BioMed

- Breaking traditional barriers in STEM
- Women's newest contributions to biomedicine
- Challenges in breaking through the glass ceiling of the traditional biomedicine field

**Moderator:** AMITA VAIDYA, Principal Scientist, Sanofi

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

11:15

*Attendees are welcome to attend co-located sessions*

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

11:40

#### Presentation 1

#### Presentation 2

Vaccines Programme

Day 1 Day 2 Day 3

12:05

*Attendees are welcome to attend co-located sessions*

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

12:30

#### Presentation 1

#### Presentation 2

Venue Information

12:55

### LUNCH BREAK

13:55



1-2-1 Meetings x3



Poster Displays



Book Now

# Day Three | Innovation & Collaboration Programme

13:55 Q&A SESSION WITH THE MORNING SPEAKERS OF THE TRACK

14:20 **Presentation 1**

**Presentation 2**

14:45 *Attendees are welcome to attend co-located sessions*

15:10 **Presentation 1**

**Presentation 2**

15:35 **AFTERNOON BREAK & REFRESHMENTS**

15:50 **Panel Discussion**

16:40 **Presentation 1**

**Presentation 2**

17:05 Q&A SESSION WITH THE AFTERNOON SPEAKERS OF THE TRACK

17:30 **End of Conference**

## BROCHURE CONTENTS

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

Book Now

LinkedIn

@OGConferences



## Novotel London West




1 Shortlands, Hammersmith International Ctre, London, W6 8DR

Discover the contemporary elegance of Novotel London West, located in the bustling heart of Hammersmith West London.

Just minutes from three of London's main tube lines (Piccadilly, District and Hammersmith & City) and located in the heart of Hammersmith; Novotel London West is ideally located for trips to Westfield London, Harrods & Kensington High Street. Also conveniently located to Heathrow Airport with excellent road and rail links to the rest of the UK. This large and modern hotel offers on-site parking (chargeable), fitness suite and complimentary Wi-Fi throughout.

### Parking

Novotel London West offers over 240 on-site car parking spaces (charged per hour for residents parking). For further information including a map and full directions, please visit: [www.novotel.com/gb/hotel-0737-novotel-london-west/index.shtml](http://www.novotel.com/gb/hotel-0737-novotel-london-west/index.shtml)

Please **[click here to visit the venue's website](#)** & to receive more information on Novotel London West 

## New to London? Why not explore a few places around the venue?

### Parks

[Hyde Park](#)

[Kyoto Garden](#)

### Markets & Shopping

[Portobello Road Market](#)

[Shepherd's Bush Market](#)

[Broadway Shopping Centre](#)

[Westfield London](#)

### Museums & Galleries

[National Gallery](#)

[V&A - Victoria and Albert Museum](#)

[The Design Museum](#)

[Leighton House](#)

### Theatres

[Lyric Hammersmith Theatre](#)

[Eventim Apollo](#)

[The Lost Estate](#)

### Pubs & Dining

[Brasserie Blanc Fulham Reach](#)

[The Dove, Hammersmith](#)

[The Blue Anchor](#)

[Jazz Cafe' Posk](#)

[Poppy's 2](#)

[The Blue Boat, Fulham Reach](#)

### Tours & Experiences

[The G Institute](#)

[Sipsmith Distillery](#)

[Fuller's Griffin Brewery Tour](#)

[Bread Angels](#)

[The Jozef Pilsudski Institute](#)

[The William Morris Society](#)

[Craven Cottage](#)

[Tardis Police Box](#)



Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

**Book Now**



BE PART OF SOMETHING EXCEPTIONAL  
**Book Now**

**Book Now**

Join our premier event to unlock the potential of the CGT value chain, from discovery and development to successful commercialisation

### Register as an Industry Delegate

If you represent a pharma or biotech research organisation primarily focused on therapeutic pipeline development, click here to secure your pass.



### Register as an Academic Delegate

If you represent an academic institution and are involved in research and development, click here to request a pass.



### Register as a Vendor Delegate

If you represent solution, technology, or service providers, commercial entities, consultants, or venture capitalists with a stake in the relevant landscapes, click here to secure your attendance



**Oxford Global PLUS Pass**



Dive into an exclusive world of knowledge with the PLUS Pass, tailored for experts, thought leaders, and innovators within the global pharma and biotech sectors

Designed to enhance your learning experience, the PLUS Pass adds a digital dimension to our curated events, fostering unlimited knowledge sharing via our PLUS Platform.

### Digital PLUS Pass - £459<sup>+VAT</sup> / \$650<sup>+VAT</sup>

Perfect for those who can't attend in person, this pass offers 12 months of on-demand access to a rich repository of event recordings, content articles, industry news, alongside participation in exclusive webinars and monthly group discussions.

### Enhanced PLUS Pass - £499<sup>+VAT</sup> / \$680<sup>+VAT</sup>

Elevate your event experience with all the benefits of the Digital PLUS Pass, plus enjoy full in-person event registration benefits. This includes provision of catered lunches and an exclusive poster display. Available during your event registration.

Whether you prefer the convenience of digital access or the enriched experience of in-person engagement, the PLUS Pass is your key to unlocking a world of knowledge and networking opportunities.

**Register Now - Digital Pass**



**View All Upcoming Events**

To receive bespoke proposal for group packages contact us at [pluspass@oxfordglobal.com](mailto:pluspass@oxfordglobal.com)

**BROCHURE CONTENTS**

Welcome

Benefits of Attending

Sponsors

Agenda at a Glance

Proteins, Antibodies & ADCs Programme

Day 1 Day 2 Day 3

Peptides, Oligonucleotide & Sustainability in Tides & Biologics Programmes

Day 1 Day 2 Day 3

Advances in Immunotherapy & Immuno-Oncology Programme

Day 1 Day 2 Day 3

Vaccines Programme

Day 1 Day 2 Day 3

Innovation & Collaboration Programme

Day 1 Day 2 Day 3

Venue Information

**Book Now**

LinkedIn

@OGConferences